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Résumé 
 Le lymphome est l'une des tumeurs les plus communes tant chez le chien que l’humain. 
Chaque année, un nombre important de chiens développe ce cancer agressif. La majorité 
décédant un an suivant le diagnostic.  Le lymphome canin est maintenant identifié comme un 
excellent modèle de recherche pour la tumeur chez l'homme, particulièrement en ce qui 
concerne la biologie moléculaire de la maladie. En conséquence, la recherche sur le lymphome 
canin sera bénéfique non seulement pour les chiens mais aussi pour l’oncologie humaine. 
Parmi les méthodes diagnostiques de choix pour dépister de façon hâtive le lymphome se 
trouve la mesure de marqueurs tumoraux. Ceci a l’avantage d’être peu invasive, simple et peu 
dispendieuse. Ainsi, dans le but d’évaluer la protéine VCP (valosin containing protein) comme 
biomarqueur tumoral dans les lymphomes canins à cellules B et T, nous avons évalué la 
protéine VCP par immunobuvardage sur sérums et tissus tumoraux de chiens atteints et par 
immunohistochimie sur des tumeurs de haut grade, grade intermédiaire et bas grade. Pour 
mieux définir l’expression de VCP dans les cellules cancéreuses, nous avons également 
examiné par immunobuvardage les niveaux de VCP dans 3 lignées cellulaires: CLBL-1, CL-1, 
et 17-71. Il s’avère que les lymphomes à cellules B de haut grade avaient une élévation 
significative du taux de VCP comparé aux tumeurs de bas grade (P < 0,05). De même, une 
accumulation importante de VCP a également été détectée dans les lignées tumorales 
comparées aux cellules mononucléaires du sang périphérique (P < 0,05). D’autre part, le taux 
sérique de VCP est resté similaire à ceux des chiens normaux. Ces résultats suggèrent une 
corrélation entre le taux de VCP et le degré de malignité des lymphomes à cellules B. En 
conclusion, la protéine VCP doit faire l’objet d’une évaluation approfondie pour déterminer 
son utilité comme marqueur pronostique.  
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Abstract 
 Lymphoma is one of the common malignancies in both dogs and humans. Annually, an 
important number of canine patients develop this aggressive cancer and a majority succumbs 
to the disease within one year. In recent years, canine lymphoma has been increasingly 
recognized as an excellent model for the disease in humans, especially with regards to the 
molecular biology of the disease. Consequently, research targeted at canine lymphoma 
benefits not only dogs but the field of human oncology as well. Among the most desirable 
diagnostic and screening tests for lymphoma is the measurement of cancer biomarkers. They 
have the advantage of being minimally invasive, simple, and inexpensive.   Thus, with the aim 
of evaluating valosin containing protein (VCP) as a cancer biomarker in canine B and T-cell 
lymphomas, we first performed western blots on sera and tumor tissue of dogs with lymphoma 
and then immunohistochemical analysis on low, intermediate and high-grade tumors. To 
further determine VCP expression in cancer cells, we also examined VCP levels by 
immunoblotting in 3 tumor cell lines: CLBL-1, CL-1, and 17-71. High-grade B-cell 
lymphomas had significantly increased levels of VCP compared to low-grade tumors (P < 
0.05). Additionally, we detected a corresponding accumulation of VCP in tumor cells lines 
compared to peripheral blood mononuclear cells (PBMCs) (P < 0.05). In contrast, VCP levels 
were not elevated in sera of dogs with lymphoma compared to healthy controls. These results 
suggest that VCP positively correlates with malignancy in canine B-cell lymphomas. We 
conclude that VCP merits further investigation to determine its potential as a clinically useful 
prognosis biomarker for canine B-cell lymphoma. 
Keywords : Valosin containing protein (p97), Cancer biomarker, Canine Lymphoma, B-cell 
lymphoma, Veterinary oncology, Dog, Malignancy 
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Introduction 
As presented in a plethora of studies, particularly in the last decade, cancer has become 
one of the major causes of death in humans and companion animals alike. The increasing 
incidence of diagnosed cases has pushed the research community to study and develop new 
screening and therapeutic methods for specific types of cancers. Among these, lymphoma, a 
common canine tumor, represents a continuing interest of research (1). 
Lymphomas are a type of cancer characterized by the proliferation of malignant 
lymphoreticular cells, or cells pertaining to both lymphoid and reticuloendothelial systems, 
within solid organs (2). The primary lymphoid organs, represented by the bone marrow and 
thymus, along with the secondary lymphoid structures, such as lymph nodes and spleen, are 
the preferred sites of neoplastic growth (3). However, due to the facilitated access of 
lymphocytes to the bloodstream and lymph, the tumor can originate virtually in any organ (4). 
In veterinary literature, lymphoma is presented as the most common hematopoietic 
canine neoplasm (4). Despite its ubiquity, the precise etiology of the disease has not yet been 
identified. Causes vary from genetic to environmental, with several breeds of dogs presenting 
a higher incidence for the disease (5). The tumor can manifest a wide spectrum of clinical and 
biological behaviours depending on its anatomical location and its stage of development (6). 
Furthermore, the symptomology of the disease can vary accordingly to the neoplastic 
transformation of either B or T-lymphocytes (7). To complicate matters even further, each 
individual tumor can present an innate heterogeneity, leaving early detection and complete 
curative therapies elusive for most veterinary patients. 
During the last 25 years of continuous treatment development, late diagnosis has 
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proven to be the major limitation on the efficacy of available lymphoma treatments. Many 
patients seem to undergo intensive chemotherapy sessions with little apparent benefit in 
metastasis control or life expectancy (8). Along the years it was understood that early tumor 
detection has a strong correlation with net gains in quality of life and prolonged survival (4). 
As such, veterinary scientists are faced with the growing clinical demand to develop and 
validate new therapeutical targets that will assist oncologists in early cancer screening.  
Among the most desirable tools for the diagnosis and prognosis of lymphomas are 
cancer biomarkers. They are defined as measurable molecules, in clinical or laboratory 
settings that appear in a modified state, quantitatively or qualitatively, in the presence of 
tumoral processes (9).  Historically, the research for biomarkers was targeted at bodily fluids 
(blood, plasma, urine) and/or tumor tissue (10). Therefore, two distinctive categories of cancer 
biomarkers emerged: serum and tumor markers. Although, both operate on the same principle, 
their detection, measurement and utility are quite different.  
Serum biomarkers are usually measured in bodily fluids, having considerable value in 
cancer screening, diagnosis, prognosis and follow-up of treatment efficacy (11, 12). As 
molecules, serum markers can be hormones, glycoproteins, or other proteins overexpressed by 
cancer cells. Although they are routinely used for screening and diagnosis of several human 
cancers, few serum markers have been identified in dogs, and none are currently used in 
clinical settings (13-15).   
The ideal serum marker should have high sensitivity and/or high specificity. More 
specifically, the test needs to discriminate cancer patients form healthy subjects and/or patients 
with benign tumors or non-cancerous conditions. Furthermore, the markers need to show 
measurable plasma levels before the manifestation of symptoms (16). The measurement of 
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targeted proteins, done by enzyme-linked immunosorbent essay (ELISA) or western blot, has 
the advantage of being minimally invasive, simple, and inexpensive (10).  
Tumor biomarkers, on the other hand, are measurable biochemical molecules 
associated with malignancy. They can be produced by tumors cells or by the body in response 
to the neoplastic process (9). Although measurement of tumor markers is only possible once 
the cancer has been identified and a biopsy has been obtained, making them ineffective for 
screening, they have an important role to play during the development of the disease (9). 
These markers are highly desirable in cancer staging, prognosis, monitoring treatment 
efficacy, and/or in evaluating the cancer’s recurrence (9). The markers can be detected in 
tissue by several immunohistochemistry and immunofluorescence protocols, immunoblotting 
and mass spectrometry (10).  
Despite their tremendous potential value, the use of serum and tumor biomarkers in 
veterinary oncology remains in its infancy. Recently, a new protein has been identified as a 
promising serum marker for human ovarian, breast, and colon cancer (17, 18). Based on our 
laboratory’s preliminary results, valosin-containing protein, or VCP, also seems to have a 
higher sensibility for certain types of canine tumors, indicative of superior potential for early 
diagnosis (17). Lymphomas are found among the specific cancers with higher expression of 
VCP during their development.  
As such, this thesis will present the evaluation of VCP expression as a cancer 
biomarker in canine lymphomas. First off, a review of the cancers in dogs and canine 
lymphoma will be presented, followed by current knowledge of the development of cancer 
biomarkers as a diagnostic tool in human and veterinary medicine, focusing on lymphoma. 
The emphasis is put on the use of serum and tissue markers as early detection and monitoring 
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tools. Next, the thesis will describe the cellular functions of VCP and will explain its potential 
usefulness as a diagnosis and prognosis biomarker for human and canine malignancies. 
Finally, the findings from this study will be presented and discussed. 
  
 
Literature Review  
 
Chapter 1: Cancer in dogs  
Recent studies identify cancer as one of the most common causes of death among 
dogs, with values as high as 30% of registered cases (19). The total incidence of neoplasia in 
the United States was estimated at 1134 cases per 100,000 dogs per year (20). In 2000, a 
Canadian study conducted by Reid-Smith and colleagues reported 4817 cases per 100,000 
dogs per year, almost four times more patients than the incidence rates reported in the States 
(20). Across the ocean, studies carried out in the United Kingdom present 2671 tumors per 
100,000 dogs per year (20). Finally, an Italian study conducted in 2008 revealed an incidence 
of 1070 cases per 100,000 dogs per year (21). The discrepancy can be a direct consequence of 
the differences in the population of dogs found in the distinct geographical territories, since 
some breeds of dogs are reported to have higher genetic predispositions for lymphoma, and/or 
the method used in tumor classification and diagnosis (20). Whatever the variables influencing 
the data might be, the overall message remains the same: a relatively high incidence of canine 
neoplasia is encountered around the world. 
The studies also presented estimated figures for the frequency of different types of 
canine tumors. Consequently, with small variations, certain types of cancers have been 
identified as having higher incidence and frequency. For female dogs, cancers of the 
mammary gland are the most significant, followed by Non-Hodgkin’s Lymphoma (NHL) and 
other connective and soft tissue tumors (21). For males, lymphoma represents the most 
important neoplasm, before skin (excluding melanoma) and soft tissue cancers (21).  
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The major limitation in presenting specific canine cancers as more prevalent revolves 
around diagnosis and detection methods. Mammary, genital and skin tumors are easily 
recognizable during a general physical exam, whereas the detection of internal cancers is less 
obvious. The latter might require specific methods of diagnosis such as imagery, exploratory 
surgery and/or histopathological consult (21). Often, the client’s decision to halt further 
clinical investigation represents a serious limitation in correctly estimating the incidence of 
different types of canine cancers such as lymphoma. 
 
1.1. Lymphoma, a type of cancer most prevalent in dogs 
Lymphomas, malignant or lymphosarcomas, are a diverse group of cancers (3). They 
present a high genetic variability with diverse, poorly understood causality (3). Clinical data 
combined with a comprehensive series of metanalyses, were able to thoroughly describe the 
biological behaviour of these cancers. In general, lymphomas have a high incidence with a 
rather aggressive development and a low life expectancy in the absence of treatment (3).  
 
1.1.1. Incidence and prevalence 
The annual incidence, or the number of new lymphoma cases per year, varies 
anywhere between 24 to 107 new cases per 100 00 dog, however there is a significant number 
of lymphoma case not recorded limiting our ability to detected the true incidence which seems 
to be much higher (3, 22, 23). In fact lymphoma occurs about 2 to 5 times in dogs as in people 
and it estimated that approximately 1 of every 15 dogs born today will get lymphoma at some 
point in his life. Incidence of lymphoma was found to increase with age, peaking at 10 years 
of age (24). As such, the incidence rates can be as low as 1.5 cases per 100,000 for dogs aged 
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less than one year, and as high as 84 cases per 100,000 for dogs older than 10 years (3). The 
maximal incidence can be found in the mid-age population, with dogs aged between 6 and 9 
years old (25).   
Although gender it is not an influential factor in lymphoma frequency, certain breeds 
appear to have a higher incidence for the disease (25). These include Golden Retrievers, 
Boxers, Bull Mastiffs, Basset Hounds, Saint Bernards, Scottish Terriers, Airedales and 
Bulldogs (26). Moreover, particular breeds present higher tendencies to develop specific types 
of lymphoma (25). Hence, Boxers and Shar-peis tend to develop alimentary lymphoma, 
Cocker Spaniels, Basset Hounds and Doberman Pinchers are more prone to develop B-cell 
lymphoma, and Boxers, Irish Wolfhounds, Siberian Huskies and Shih Tzus present more often 
than not T-cell lymphoma (27). Finally, Golden Retrievers can indiscriminately develop B or 
T-cell lymphomas (3).  
Historically, lymphomas have a lower risk of appearance in intact females and in 
certain breeds, namely, Dachshunds and Pomeranians (3). Furthermore, because of closed 
gene pools and repeated inbreeding, purebred dogs present slightly higher tumor rates than 
crossbred dogs (28). 
Lymphoma prevalence, also known as the cumulative incidence, is estimated at 7% to 
24% of all canine neoplasia, with an average of 20% (3, 27). Among the hematopoietic 
malignancies, lymphoma occupies a staggering 83% of all registered cases (3). The most 
prevalent are the solid forms, such as lymphosarcomas and malign lymphomas (25). Within 
the solid forms, the most common type is diffuse large B-cell lymphoma, a similarity canis 
familiaris shares with humans (27). 
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1.1.2. Causes  
The causes of lymphoma, despite extensive research, are still not completely 
understood and likely multifactorial. Among the etiological factors that trigger the cells’ 
aberrant multiplication we can distinguish: genetics and molecular causes, infectious and 
environmental factors, and immunosuppression (3). 
The recent advances in coding the canine genome have allowed detection of 
chromosomal aberrations in dogs affected by lymphoma. As such, studies have reported 
genetic material gain on canine chromosomes 13 and 31 and loss of it on chromosome 14 (3). 
Among other molecular events leading to tumorigenesis, deoxyribonucleic acid 
hypomethylation, and mutation of genes p53 and N-ras are common features of cancerous 
lymphocytes (3). The cellular pathways of the Bcl-2 family also seem to be involved in the 
process, however, more research is needed in order to fully understand their complete 
implication (3). 
Besides the genetic causes, several studies have made a link between lymphomas and 
infectious and/or environmental factors. A weak association has been proposed between 
Helicobacter pylori infections and the development of gastric lymphomas (3). Viral infections 
appear to trigger the formation of mucosa-associated lymphoid tissue (MALT) lymphoma (3). 
Environmentally, the tumor appears to be related to the use of phenoxyacetic acid herbicides, 
particularly 2,4-dicholorophenoxyacetic acid (2,4-D) (3). In households were the substance 
was regularly used, dogs developed malignant lymphoma twice as frequently as in households 
where environmentally friendly or no herbicides were employed (3). In recent literature, there 
is a debate concerning the correlation between strong magnetic fields and the increased risk of 
canine lymphoma (25). Although the evidence is scarce, one study reported that dogs living in 
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households with very high current codes were 6.8 times more inclined to develop the disease 
(28).  
Finally, immunosuppression is considered an important risk factor in the development 
of lymphomas. Immune system alterations, such as immune-mediated thrombocytopenia and 
immunosuppressive therapies (e.g., cyclosporine) are reported to help in the development of 
the neoplastic process (3). 
 
1.1.3. Clinical findings  
 The prevalent ontogenic site of lymphomas is the lymphoid tissue (lymph 
nodes, spleen and bone marrow), however, almost any tissue can be affected (3). Due to this 
variability in anatomical locations, lymphoma presents with variously different clinical signs 
which are most often site dependent (29). 
Multicentric lymphoma, the most common form encountered, presents a painless 
generalized lymphadenopathy, often accompanied by hepatosplenomegaly and bone marrow 
infiltration (3). The attack on the bone marrow provokes blood dyscrasias, a condition 
associated with anemia, thrombocytopenia and neutropenia (3). Due to the incapacity of the 
myeloid stem cells to replicate, the disorder can also lead to fever, sepsis and/or hemorrhage 
(3). Occasionally, the lesions will lead to nonspecific signs such as anorexia, weight loss, 
vomiting, diarrhea, emaciation, ascites, dyspnea, polydipsia, polyuria, and fever (3). T-cell 
lymphoma, a subtype of multicentric lymphoma, can add hypercalcemia to the long list of 
symptoms (25).  
In the case of gastric or alimentary lymphoma, lesions to the mucosa and lamina 
propria will cause vomiting, diarrhea, weight loss, panhypoproteinemia, and malabsorption 
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(3). As secondary lesions, the tumor could metastasize to the mesenteric and pelvic lymph 
nodes, spleen and liver (3). 
Canine lymphomas can also be encountered in the mediastinal cavity, where lesions 
create their own set of clinical symptoms. These types of tumors are characterized by the 
enlargement of the craniomediastinal structures and/or the thymus (3). Depending the extent 
of the disease, the animal might present with one or more of the following signs: respiratory 
distress, pleural effusion, exercise intolerance, regurgitation, polydipsia, polyuria, and possible 
hypercalcemia (3). If the mass compresses or invades the cranial vena cava, a pitting edema of 
the head, neck, and forelimbs might be observed (3).  
The lesions for extranodal lymphomas are organ specific and, although important, their 
description exceeds the scope of this thesis. It is worth mentioning the involvement of tumors 
in the central nervous system (CNS) because of their serious consequences such as: 
paraparesis, ataxia, hyperesthesia, blindness, lethargy, and seizures (3). 
 
1.1.4. Classification 
Over the years, several classification systems have been used to differentiate between 
the various types of lymphomas. As such, the tumors can be classified on the basis of 
anatomical location, histopathological description and immunophenotypic analysis (3). 
 
1.1.4.1. Anatomical classification 
Multicentric lymphoma is encountered in approximately 80% of cases (29). It has the 
aspect of a ganglionary, rubbery, painless, mobile, smooth, and generally symmetrical tumor 
(25). The adenomegaly first affects the submandibular and retropharyngeal lymph nodes, 
 11 
however, if left untreated, it will spread to other organs and parts of the lymphoreticular 
system (25).  
The second most encountered form, representing 7% of cases, is gastrointestinal or 
alimentary lymphoma (29). The digestives lesions, mostly ulcers, can have different stages of 
infiltration throughout the submucosa and lamina propria (25). Mesenteric, gastric and 
retrocaecal adenopathies can be observed in the last stages of the disease (25). Historically, it 
was believed that alimentary lymphoma originates form B-cell lymphocytes, however, recent 
findings place the origin of the tumor as T-cell derived neoplasia (3).  
Six percent of dogs affected by lymphoma develop the cutaneous or mucocutaneous 
form (29). The tumor is characterized by non-specific skin changes, progressing from scaly 
alopecia to thickened erythematous ulcerations to plaque-like lesions (29). Recent 
classifications have distinguished between two forms: epitheliotropic cutaneous and non-
epitheliotropic cutaneous lymphomas (25). Epitheliotropic cutaneous lymphoma is 
encountered more often and is characterized by multicentricity and slow development, 
originating most often from CD8+ T-cells (3, 25). The latter type, although rarely encountered 
in clinical settings, develops in the deep dermis, being more invasive and difficult to treat (25). 
Extranodal forms of lymphoma are rarely encountered, with a prevalence of only 3% 
of cases (29). The tumors appear randomly with predilections for eyes, central nervous system, 
bones, testis and nasal cavity (29). The form specific to the central nervous system is known as 
intravascular or angiotrophic lymphoma (3). It originates from either B or T-cell lymphocytes, 
and is characterized by diffuse infiltration of the wall and lumen of blood vessels (3).  
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1.1.4.2. Histopathological classification 
Due to numerous cellular analogies between human and canine malignancies, the 
histological classification systems have been adapted from human oncology (25). The current 
systems used in veterinary medicine include the Kiel classification, Working Formulation 
(WF) and World Health Organization (WHO) (3). 
The Kiel classification is useful in distinguishing between B or T-cell tumors and in 
differentiating between high grade or low grade malignancies (25). We present the identifiable 
types of lymphoma using this system in table 1.  
Table 1. The updated Kiel classification of canine lymphomas (25) 
B-cell lymphomas T-cell lymphomas 
Low malignancy lymphomas 
Lymphocytic B-cell lymphoma 
Lymphoplasmacytic/limphoplasmacytoid 
Lymphoma 
Plasma cell lymphoma 
Centrocytic lymphoma 
Centroblastic – centrocytic lymphoma 
Lymphocytic T-cell lymphoma 
Small cerebriforms cell lymphoma (Mycosis 
fungoides) 
Pleomorphic small cell lymphoma 
 
High malignancy lymphoma 
Monomorphic centroblastic lymphoma 
Polymorphic centroblastic lymphoma 
Immunoblastic B-cell lymphoma 
Burkitt lymphoma 
Lymphoblastic B-cell lymphoma 
Pleomorphic mixed cell lymphoma 
Pleomorphic large cell lymphoma 
Immunoblastic T-cell lymphoma 
Anablastic lymphoma 
Lymphoblastic T-cell lymphoma 
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The WF, developed by the National Cancer Institute, categorizes lymphomas as low, 
intermediate, and high grade, with no distinction between B or T-cell origin (3, 25). The 
tumoral classification mainly uses cytomorphological characteristics such as size, type (small 
cleaved cells, large cells, and immunoblastic cells), shape of the nucleus, and the architecture 
of the neoplastic tissue (follicular or diffuse) (25). The WF classification (table 2) is used to 
analyze the biology of the tumor and is better at predicting patient survival (3). 
Table 2.  The WF classification of Non Hodgkin’s Canine Lymphomas (25) 
 
 
Low malignancy lymphomas 
Small cell lymphocytic lymphoma: 
      - Diffuse small cell lymphocytic lymphoma 
      - Plasmocytoid lymphoma 
Small cleaved cell follicular lymphoma 
Mixed small cleaved cell 
Large cell follicular lymphoma 
 
 
Intermediate malignancy lymphomas 
Large cell follicular lymphoma 
Diffuse small cleaved cell lymphoma 
Diffuse mixed small and large cell lymphoma 
Diffuse large cell lymphoma 
Diffuse large non-cleaved cell lymphoma 
 
 
High malignancy lymphomas 
Large cell immunoblastic lymphoma 
Convoluted cell lymphoblastic lymphoma 
Non-convoluted cell lymphoblastic lymphoma 
Burkitt lymphoma 
 
 
Other types of lymphomas 
 
Mixed lymphoma 
Mycosis fungoides 
Extramedullary plasmocytoma 
Histiocytic lymphoma 
Unclassifiable forms 
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The Veterinary Lymphoma Study has recently adapted the latest WHO classification 
of neoplastic diseases of lymphoid tissue in humans (30). The classification was developed to 
incorporate both morphological, genotypic, and immunohistologic criteria, thereby providing a 
system for categorizing lymphoid neoplasms according to the level of cellular maturation (3). 
The strength of this system resides in the capacity to categorize canine lymphomas within the 
B or T-cell subtypes as well as offering a clinical prognosis (31). The WHO classification 
combines with success the previous two systems, insuring a better diagnostical uniformity 
among veterinary pathologists.  
 
1.1.4.3. Immunophenotypical classification 
The development of monoclonal antibodies has made possible the detection of specific 
markers on the surface of lymphocytes, giving more insight into the classification of canine 
lymphomas. Based on this method, lymphomas are further differentiated into B, T or null-cell 
(neither B or T immunoreactive) tumors (29). The immunophenotypic classification has lead 
to the realization that most canine lymphomas have a B-cell immonophenotype (25). Thus, as 
presented by the veterinary literature, B-cell lymphoma accounts for 60% to 80% of cases, T-
cell lymphomas for 10% to 38%, mixed B and T-cells for 22%, and null-cell for fewer than 
5% (3). Furthermore, classifying lymphomas with the help of monoclonal antibodies led 
pathologists to the conclusion that T-cell lymphomas have a higher incidence than previously 
recorded (25). Clinically, making a clear distinction between a T-cell or a B-cell derived tumor 
has major importance since the latter can be more aggressive and present a lower response rate 
to treatment (25).  
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1.1.5. Diagnosis 
When suspecting lymphoma, the veterinary clinical oncologist has to perform a 
thorough clinical evaluation which includes a complete physical examination, blood work, 
serum biochemistry, and urinalysis (3). Advanced imaging modalities like computer 
tomography, magnetic resonance imaging, and positron emission/computed tomography are 
becoming more accessible in veterinary medicine (3). The final diagnosis is largely given by 
the veterinary pathologist who will employ histologic and cytologic tissue evaluation, 
molecular analysis, immunophenotyping, and clonality assay as diagnostic tools (3).  
Histological and cytological evaluations can be done on biopsied tissue using 
histochemical/immunohistochemical and cytochemical/immunocytochemical staining and/or 
flow cytometry (3). Although all protocols are clinically available, for the moment 
immunophenotyping seems to be the most reliable (3). The technique uses specific cellular 
membrane markers to improve the precision of diagnosis and provide the clinician with a 
certain prognosis (3). Antibodies against CD3+, CD4+ and CD8+ for T-cells and CD79a+ and 
CD21+ for B-cells are applied against tissue sections (immunohistochemistry), cytologic 
specimens (immunocytochemistry), or single cells (flow cytometry) (3). When the 
characterization of lymphomas proves to be challenging utilizing standard histology, PCR 
techniques are used to amplify the genes of the immunoglobulin receptor for either B or T-cell 
lymphocytes (3).  
Once the precise diagnosis is reported by the pathologist, the WHO classification 
system (Table 3) is used to stage the tumor (3). Stages I and II are more favorable if index “b” 
is not present, however, the other higher stages carry with them a poor prognosis (25). Stage V 
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leads for the most part to the death of the animal in a matter of days to weeks (25). Because 
lower stages are asymptomatic and regular medical examination is not standard veterinary 
practice, most dogs present with advanced stages, thus reducing drastically the treatment’s 
efficacy (3). 
Table 3. WHO clinical staging for domestic animals with lymphoma 
Stage Criteria 
 
I 
Single lymph node 
a. Without clinical sign of disease 
b. With clinical signs of disease 
 
II 
Multiple lymph nodes in a regional area 
a. Without clinical signs of disease 
b. With clinical signs of disease 
 
III 
Generalized lymphadenopathy 
a. Without clinical signs of disease 
b. With clinical signs of disease 
 
IV 
 
Liver and/or spleen involvement (with or without stage III) 
a. Without clinical signs of disease 
b. With clinical signs of disease 
 
V 
Bone marrow or blood involvement and/or non-lymphoid organ 
(with or without stage I-IV) 
a. Without clinical signs of disease 
b. With clinical signs of disease 
 
1.1.6. Treatment 
In clinical practice treatment options and the order of their administration differ from 
patient to patient, depending on the type of lymphoma and the extent of the disease. The 
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current golden standard in veterinary oncology concerning lymphoma treatment includes: 
systemic chemotherapy and immunotherapy, radiation therapy, and surgery (29). 
 
1.1.6.1. Chemotherapy 
Veterinary oncologists have at their disposal a variety of chemotherapeutic protocols 
that can be adapted according to the stage and substance (the presence or absence of clinical 
signs) (12), the presence of paraneoplastic syndrome, and the dog’s overall physical condition 
(3, 29). Moreover, the owners’ financial situation and time constraints, along with possible 
apprehension vis-a-vis the side effects of treatment, may also play a deciding factor (3, 29).  
 Multidrug chemotherapy protocols were first introduced over 20 years ago and have 
developed considerably since (3, 29). The most used treatment is a modification of the CHOP 
protocol, used for the first time in human oncology (3). This first line treatment is composed 
of cyclophosphamide (C), hydroxydaunorubicin or doxorubicin (H), oncovin or vincristine (O) 
and prednisone (P) (32). For this protocol, remission rates can reach 80% to 90% and can 
present an average survival time of 8 to 12 months (29). In 20 to 25% of cases, survival times 
might be as high as two years, albeit complete healing can rarely be achieved (25).  
When the CHOP-based protocol does not represent a desirable option, the oncologist 
can implement a single agent chemotherapy protocol. Several pharmaceutical agents are 
available: doxorubicin, L-asparaginase, polyethylene glycol-L-asparaginase, vincristine, 
cyclophosphamide, and prednisone (3). This type of protocol is often avoided as single agent 
chemotherapy induction does not lead to long-lasting remission, with the exception of 
doxorubicin (3). Compared to a complex chemotherapy treatment, a non-doxorubicin 
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treatment protocol has more often than not resulted in short-lived remission and survival 
times, and higher chances of developing multi drug resistance (3). 
Despite the existence of several induction chemotherapy protocols, the majority of 
dogs will relapse (29). Several theories are trying to account for this regression, although the 
most accepted in the scientific literature is the emergence of multiple drug resistant cancer 
cells (25). Treating a patient with chemotherapeutic regimens exerts strong selective pressure 
on tumor cells: those that have activated genes that reduce their susceptibility to drugs will 
survive treatment and continue proliferating while those that have not will die. 
Chemoresistance comes in many forms, from molecular pumps that remove drugs from cells 
to impaired DNA damage response mechanisms that allow damaged cells to continue dividing 
In the eventuality the tumor will develop such cells, a new chemotherapy protocol has to be 
initiated: the reinduction protocol. The treatment is started with the previously used protocol 
and changed if remission delays appear (3). Favourable results are obtained in only 50% of 
cases with better outcomes if the patient fully completed the initial induction protocol (25). 
The last resort for treating a lymphoma with the help of chemotherapy is the rescue 
protocol (29). The drugs used in a single agent or combination protocol may include, but not 
exclusive to, actinomycin D, mitoxantrone, lomustine etc. (33-35). The overall response rates 
rarely exceed 40% to 50% and the remission is short lived, with an average remission time of 
one and a half to 3 months (25). 
Although chemotherapy is the treatment of choice in veterinary hospitals and clinics, 
the effectiveness of this method seems to have reached its limits. For the last couple of years, 
no important changes have been recorded in response and remission rates. New generations of 
chemotherapeutic drugs are needed along with the development of non-chemotherapeutic 
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agents such as immunoconjugate therapies (an antibody conjugated to a second molecule, 
usually a toxin or radioisotope) (36).  
 
1.1.6.2. Immunotherapy 
In recent years, several specific (i.e. bacterial vaccines) and non-specific (analogous 
lymphatic cells, monoclonal antibodies, anti-tumoral cell) immunotherapy trials have been 
developed (13). Unfortunately, these new treatment options have not yet passed phase two of 
clinical trials, leaving veterinary oncology without a viable chemotherapy replacement. 
 
1.1.6.3. Radiation therapy 
Used frequently in human oncology, radiation therapy has been used in veterinary 
medicine only for selected cases (3). Trained oncologists have the option of performing focal, 
whole body or half-body radiation. Focal radiotherapy is usually reserved only for localized 
stage I and II tumors (3).  Whole body irradiation becomes a viable option when bone marrow 
transplant can be performed, and half-body irradiation only when the animal is in remission 
(3). Present investigations are in place to determine if radiation therapy could be used between 
chemotherapy sessions to reduce treatment length and induce faster remission (3). 
 
1.1.6.4. Surgery 
Curative surgical resection can only be used for ganglionary stage I that is localized 
and solitary extranodal lymphomas (25). Alimentary and cutaneous forms are the best 
candidates for this form of treatment (25). Dogs that present with massive splenomegaly can 
only benefit from splenectomy only when the cancer is not responsive to chemotherapy (37).  
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1.1.7. Prognosis 
Historically, survival times for canine lymphoma have been associated with a number 
of factors, namely: the location of the disease, clinical stage, presence of clinical signs, 
histological grade, immonophenotype, previous treatment, development of multi-drug 
resistance, tumour’s apoptosis and proliferation rate, presence of previous medical conditions, 
and paraneoplastic syndrome (3). According to the WHO, stage I and II carry a more 
favourable prognosis especially when associated with high and medium histopathological 
grades (3). Although high-grade tumors are normally associated with reduced survival times, 
in low stages they respond better to treatment. This is explained by their high mitotic rate 
which is directly targeted by the chemotherapeutic agents (3). For the same stage and grade a 
comparison between B-cell and T-cell lymphomas has shown for the latter shorter remission 
and survival times, especially when associated with hypercalcemia and reduced renal function 
(38, 39).   
The multifactorial aspect of the disease makes it difficult to provide the client with a 
precise prognosis. Once the diagnosis is established, untreated dogs are expected to live 4 to 6 
weeks, with some exceptions in the case of low-grade tumors (29). The prognosis improves to 
8 to 12 months when the appropriate treatment is provided, however, the disease remains 
aggressive by nature and full recovery is rarely attained. 
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Chapter 2: Development of cancer biomarkers as tools for improving disease detection  
          and treatment 
 
2.1. Cancer biomarkers  
 Clinically, most cancers could be curable by conventional therapies if detected 
prematurely. Early, non-invasive cancer screening has been a long time endeavour for the 
scientific community. The realization that cancers could overexpress distinct biomolecules, in 
addition to the development of the field of proteomics, made scientists’ efforts easier in 
identifying molecules overproduced in malignant processes. In turn, this has led to the 
possibility of early cancer detection and the development of individualized target therapies. As 
such, in the last decade, much attention was given to cancer biomarkers as a non-invasive and 
economically affordable method of diagnosis and treatment.  
 Cancer biomarkers can be defined as measurable molecules found in biological tissues 
or fluids that act as a surrogate indication for the presence of a tumor (40). They may be 
produced by the tumor itself or by the host in response to the presence of the tumor (40). The 
molecules may be measured qualitatively or quantitatively by several methods such as 
proteomic, genomic or chemical to determine their presence (40). The ideal tumor marker 
should be both specific and sensitive for the detection of a certain type of tumor early in its 
progression. Currently, most tumor markers are not sensitive or specific enough to be used in 
routine population screening and are used in monitoring patients after therapy (40).  
 Cancer biomarkers can take many different forms such as: DNA, RNA, proteins, gene-
expression and proteomic signature, methylation patterns, metabolites, carbohydrates and 
lipids (40). The nucleic acid analysis has revealed that cancer cells can be detected due to 
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DNA based mutations, single nucleotide polymorphisms, altered expression of certain genes 
and epigenetic modifications that alter gene expression (41). Moreover, scientists realized that 
changes in peptide and protein levels could also represent a reliable way to detect malignant 
tumors (41). The small molecule metabolites resulting from the metabolic pathways of cancer 
cells, together with the concentration of certain micronutrients by some cancers represent yet 
another opportunity to identify tumors in their early stage of growth (41).  
 The opportunity to identify candidate cancer biomarkers has materialized in the past 
decade with the completion of the human genome sequence and the introduction of high 
throughput sequencing technologies, microarrays and mass spectrometric approaches for the 
identification of proteins. As a result, there have been large efforts in developing methods to 
identify novel cancer biomarkers that show clinical utility for diagnosis, prognosis or 
therapeutic monitoring. Two main approaches, genomic and proteomics are applied in today 
laboratories to the search for cancer biomarkers.    
 Historically, cancer biomarkers have been divided into serum and tumor markers, each 
with its own specific clinical application (16). Besides their biological classification, in human 
oncology three major utilitarian definitions have emerged for biomarkers: diagnostic 
biomarker, prognostic biomarker, and stratification or predictive biomarker (42). Diagnostic 
biomarkers are defined as molecules used to detect a specific type of cancer (42). On the other 
hand, prognostic biomarkers are used once the patient has a definite diagnosis and the 
clinician needs to predict the probable course of the disease including its recurrence (42). 
Finally, the measurement of a stratification biomarker is made when there is a need to 
predicting the response to a drug before treatment is started (42). In this case, the marker is 
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used to look for specific characteristics of the tumor that will inform the oncologist if the 
patient is likely to be responsive to treatment (42).  
 Besides the well-established clinical applications, cancer biomarkers have extended in 
the last decade into all the major segments of the treatment continuum. Table 4 depicts the full 
extent of the possible clinical utility of biomarkers according to their type.  
Table 4. Use of cancer biomarkers in patient care (40) 
Clinical Biomarker Use Clinical objective Type of marker 
Risk stratification 
Assess the likelihood that cancer will 
develop or recur 
Serum 
Chemoprevention 
Identify and target molecular mechanisms 
of carcinogenesis in precancerous tissues 
Tumor 
Screening 
Detect and early-treat cancers in the 
asymptomatic population 
Serum 
Diagnosis 
Definitely establishes the presence of 
cancer 
Serum 
Classification Classify patients by disease subset  Tumor  
Prognosis 
Predict the probable outcome of cancer 
regardless of the therapy, to determine the 
aggressiveness of treatment  
Tumor 
Prediction/Treatment 
stratification 
Predict response to particular therapies 
and choose the drug that is most likely to 
yield a favourable response in a given 
patient  
Tumor 
Risk management  
Identify patients with a high probability 
of adverse effects of a treatment  
Tumor/Serum 
Therapy monitoring  
Determine whether a therapy is having 
the intended effect on a disease and 
whether adverse effects arise 
Tumor 
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Post-treatment surveillance  
Early detection and treatment of recurrent 
disease  
Serum 
Target validation 
Demonstrate that a potential drug target 
plays a key role in the disease process  
Tumor 
Early compound screening 
Identify compounds with the most 
promise for efficacy and safety 
Serum 
Pharmacodynamic assays  
Determine drug activity; select dose and 
schedule 
Tumor  
Patient selection 
In clinical trials, patient selection by 
disease subset or probability or 
response//adverse events  
Serum 
Surrogate end-point 
Use of a short-term outcome measure in 
place of the long-term primary endpoint 
to determine more quickly whether the 
treatment is efficacious and safe in drug 
regulatory approval  
Tumor  
 
 Clinical efficacy and analytical robustness are two of the main criteria used in selecting 
cancer biomarkers for use (16). A biomarker should be specific for its application, be it 
screening, prediction or therapeutic response monitoring. Overall it should exhibit high 
sensitivity and specificity with a high area under curve (AUC) in a receiver operating 
characteristic curve (ROC) (16). It should also be well-defined biochemically with the 
possibility of detection by reagents such as antibodies (16). The analytical method for 
measuring the marker should be accurate and precise with no cross-reactivity and should be 
automated for efficient execution (16, 40). In the following sections, this thesis will 
summarize the clinical efficacy of cancer biomarkers both in human and veterinary medicine. 
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2.2. Cancer biomarkers in human medicine 
 The emergence of evidence-based medicine in the late 19th century compelled human 
oncology to develop early ideas about premature cancer detection and personalized therapies. 
Consequently, human medicine already benefits from several FDA (Food and Drug 
Administration) approved cancer biomarker tests. The tests use quantifiable molecules to 
diagnose, prognose, monitor cancerous processes and evaluate treatment response (16). It is 
worth mentioning that, despite obvious progress, biomedical research has not yet been able to 
develop any reliable biomarker-based tests for early cancer screening.    
The published literature reveals that in human medicine biomarkers of interest can be 
measured in serum or plasma, tumor, in vivo, urine, proximal fluids (pancreatic juices, 
ascites), exhaled breath, etc. (16). Due to the minor importance of the other sampling sources, 
this thesis will focus mainly on the utility of serum and tumor markers.  
 
2.2.1. Serum markers in human medicine  
 Several serum biomarkers, mostly tumor derived soluble proteins, have been identified 
and are presently used in clinical settings (16). As aforementioned, their main clinical benefit 
is the ability to diagnose cancer and monitor its recurrence (16). The molecular biomarkers 
summarized in the table 5 are approved for clinical practice, thus used in oncological settings. 
Despite their large-scale usage none is clinically used in veterinary medicine.  
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Table 5. FDA approved serum biomarkers (16, 43) 
Biomarker Type Condition Indicated use Sample 
AFP 
(immunoassay)  
Tumor-derived 
plasma protein 
Nonseminomatous 
testicular cancer, 
foetal neural tube 
defects  
Patient 
management, 
monitoring of 
disease progression 
Serum  
CA125 
(immunoassay) 
Tumor-derived 
plasma protein 
Ovarian cancer 
Patient 
management, 
monitoring of 
disease progression 
Serum 
CA15-3 
(immunoassay) 
Tumor-derived 
plasma protein 
Breast cancer  
Patient 
management, 
monitoring of 
disease progression 
Serum 
CA19-9 
(immunoassay) 
Tumor-derived 
plasma protein 
Pancreatic cancer 
Aid in patient 
management  
Serum/plasma 
CEA 
(immunoassay)  
Tumor-derived 
plasma protein 
Multiple cancers 
Patient 
management, 
monitoring of 
disease progression 
Serum/plasma 
Urine 
HE4 
(immunoassay)  
Tumor-derived 
plasma protein 
Ovarian cancer 
Patient 
management, 
monitoring of 
disease progression 
Serum 
OVA1 (5 
markers panel: 
APOA1, B2M, 
CA125, TF, 
TTR, 
immunoassay) 
Tumor-derived 
plasma protein 
Ovarian cancer  Aid in diagnosis Serum 
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PSA 
(immunoassay) 
Tumor-derived 
plasma protein 
Prostate cancer 
Diagnosis, patient 
management, 
monitoring of 
disease progression 
Serum 
ROMA (2-
Marker panel: 
CA125, HE4, 
immunoassay)  
Tumor-derived 
plasma protein 
Ovarian cancer Diagnosis Serum  
Alpha-
Fetoprotein 
(AFP) 
Glycoprotein 
Nonseminomatous 
testicular cancer  
Staging  Serum 
Human 
chorionic 
gonadotropin-
beta  
Glycoprotein Testicular cancer Staging Serum 
Thyroglobulin 
(Tg) 
Protein Thyroid cancer Monitoring Serum 
Progesterone 
receptor 
HER2/NEU  
Protein Breast cancer 
Monitoring, 
prognosis, therapy 
selection 
Serum/Tumor  
 
 Increasing research in the field of proteomic cancer profiling will most likely allow the 
discovery of new serum biomarkers (41). All the same, special attention has to be given to the 
improvement of present tests. Today’s cancer biomarkers tend to have high sensitivity but low 
specificity since they do not detect cancer per se but rather a general cellular process 
intensified during pathological dysplasia (44). In this sense, early cancer detection proves to 
be a difficult task as numerous pathologies can have as a side effect an increased level of the 
molecule (41). Furthermore, not all cancer patients express high serum marker levels and 
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when they do, the cancer is too advanced, making the tests obsolete (41). To complicate 
matters even more, the majority of the biochemical and biocellular pathways involved in 
cancer growth are permanently active as part of the normal homeostatic process. Therefore, 
almost everyone has a trace amount of the interest molecule in their blood, thereby increasing 
the number of false positive tests (41). As such, it is imperative to remember that although an 
aggressive investigative approach may be warranted on the basis of raised serum marker 
values, treatment cannot be initiated without a confirmatory pathological report (44). For the 
moment, the development of a marker that would prove to be such a precise diagnostic tool is 
still in its infancy.  
 
2.2.1.1. Specific serum markers for Lymphoma 
 Generally, the diagnosis of haematological cancers represents a difficult task. The 
malignant cells have the capacity of arising from different stages of hematopoietic 
differentiation giving birth to heterogeneous tumors (40). In recent years, several scientific 
advances have led to a better understanding of the biochemical processes underlying 
haematological malignancies. As such, potential biomolecular targets, with possible 
applications in detection, prognosis, and treatment monitoring, have been identified (40). 
Lymphoma was not deprived of the scientific advancement; several serum biomarkers have 
been acknowledged in human oncology. Table 6 presents the biomarkers that are of most 
interest, with the mention that only a small number are presently used in clinical settings 
mainly due to their low specificity or sensitivity (40).   
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2.2.2. Tumor markers in human medicine  
 Cancer is a heterogeneous disease. During the tumorigenic process, different genetic or 
epigenetic lesions may occur that can result in distinct transcriptome, which is associated with 
a distinct tumor phenotype (51). Gene expression profiling (GEP) using microarray platforms 
represent a powerful tool to explore the expression of thousands of gene simultaneously (51, 
Table 6. Lymphoma serum biomarkers identified in current literature (45-50)  
Biomarker Type Condition Indicated use Sample 
Serum 
Deoxythymidine 
(immunoassay) 
Protein 
(enzyme) 
Non-Hodgkin’s 
Lymphoma 
Prognostic and 
monitor of 
patients  
Serum 
Serum Ferritin  Protein Lymphomas  
Patient follow-
up 
Serum 
Interleukin-2 
Receptors 
Protein 
Non-Hodgkin’s 
Lymphoma 
Prognostic 
significance for 
survival 
Serum 
Beta-2 
Microglobulin 
Protein 
Non-Hodgkin’s 
Lymphoma 
Prognostic 
significance for 
survival 
Serum 
CA125 
Tumor-derived 
plasma protein 
Non-Hodgkin’s 
Lymphoma 
Staging, 
monitoring and 
follow-up  
Serum  
TNF-R1 and 
CD27 
(theoretical 
stage) 
Proteins 
Non-Hodgkin’s 
Lymphoma 
Cancer 
screening 
(increased future 
risk of NHL)  
Serum 
C-reactive 
Protein 
Protein 
Non-Hodgkin’s 
Lymphoma 
Prognosis Serum 
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52). In the context of cancer, GEP has been used to accurately classify tumors or define tumor 
subtypes. The molecular signatures derived from gene expression profiling might have an 
impact on diagnosis, prognosis, and therapy selection (52).  
 Recently, in human cancer studies, the application of a range of different microarray-
based technologies such as, array-based comparative genomic-hybridization (CGH), cDNA 
microarray, and methylation array, has increased the understanding of cancer development, 
and, more importantly, has generated a large number of candidate molecular markers with 
potential clinical value (40). While several tumor biomarkers have made the object of clinical 
trials in the recent decade, due to inconclusive results, side effects of personalized treatments, 
or low efficacy compared to the golden standard, only a small number are present in clinical 
settings (40). Table 7 presents the FDA approved markers used in human medicine. Similar to 
serum markers, none of these molecules have applications in veterinary medicine. 
 
Table 7. FDA approved tumor biomarkers (16) 
Biomarker Type Condition Indicated use Sample 
BRAF mutation 
(real time PCR) 
Tumor DNA 
mutation 
Melanoma 
Treatment 
response 
FFPE Tissue  
(Formalin Fixed 
Paraffin 
Embedded 
Tissue) 
C-KIT (IHC) 
Tumor-derived 
plasma protein 
Gastrointestinal 
caners 
Diagnosis, 
Treatment 
response  
FFPE Tissue 
EGFR (IHC) 
Tumor-derived 
plasma protein 
Colorectal 
cancer 
Treatment 
response 
FFPE Tissue 
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   Mammaprint 
DNA microarray 
Gene expression 
signature 
Breast cancer Prognosis Fresh tissue 
TOP2A (FISH)  
Chromosomal 
aberration  
Breast cancer Prognosis FFPE Tissue  
 
2.2.2.1. Specific tumor markers for lymphoma 
 Non-Hodgkin lymphoma (NHL), or more commonly known as the solid tumor of 
lymphocytic origin, has the highest incidence among hematopoietic cancers in humans (53, 
54). It is the fifth most common cancer in North America and its incidence has been increasing 
over the last three decades (54). NHL comprises a group of clinically and biological diverse 
diseases, which range from indolent to aggressive clinical course. Although, 
immunochemotherapy has significantly increased complete remission rates, leading to 
improved survival, cure rates reach only around 60% (55). Patients that develop resistance to 
the primary drug regiments have a poor survival, even with subsequent high-dose 
chemotherapy (55). Moreover, primary refractory patients have a dismal outcome (55). Many 
new treatment strategies are being explored, some involving targeted molecules (55). 
 A myriad of tumor markers have been described to help significantly increase survival 
rates. However, the field is constantly becoming more complex, and few markers have been 
validated in independent studies and have moved to controlled clinical trials. A PubMed 
search was performed using the terms “tumor biomarkers”, “lymphoma”, “prognosis”, 
“outcome”, and “survival”. Priority was given to studies analyzing the biomarkers already in 
clinical use. Table 8 summarizes the tumor biomarkers identified in the current literature.  
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Table 8. Tumor biomarkers for lymphoma identified in the current literature (55-59) 
Biomarker Type Condition Indicated use Sample 
MYC/BCL2 
(double-hit) 
Genetic 
abnormality 
Diffuse Large B-
Cell Lymphoma 
Treatment 
response, 
Prognosis  
FFPE Tissue  
CD20 
Transmembrane 
Protein 
Lymphoma (better 
results for Diffuse 
Large B-Cell 
Lymphoma) 
Treatment 
(Immunochemoth
erapy) 
FFPE Tissue 
LMO2, BCL6, 
FN1 
Gene 
overexpression 
Diffuse Large B-
Cell Lymphoma 
Prognosis FFPE Tissue 
CCND2, 
SCYA3, BCL2 
Gene 
overexpression 
Diffuse Large B-
Cell Lymphoma 
Prognosis FFPE Tissue  
CD30  
Transmembrane 
Protein 
Anaplastic Large 
Cell Lymphoma 
Treatment 
(Immunochemoth
erapy) 
FFPE Tissue  
ALK-NPM1 
Chromosomal 
translocation 
Anaplastic Large 
Cell Lymphoma 
Diagnosis FFPE Tissue 
C-MCY, IGH-
BCL2, BCL6 
Chromosomal 
translocation 
Diffuse Large B-
Cell Lymphoma/ 
Burkitt Lymphoma 
Diagnosis FFPE Tissue 
IGH-BCL2 
Chromosomal 
translocation 
Follicular 
Lymphoma 
Diagnosis FFPE Tissue 
CCND1-IGH 
Chromosomal 
translocation 
Mantle-Cell 
Lymphoma 
Diagnosis FFPE Tissue 
API2-MALT1 
Chromosomal 
translocation 
Marginal Zone 
Lymphoma  
Diagnosis FFPE Tissue 
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Chapter 3: Cancers biomarkers in veterinary medicine  
Although routinely used for screening, diagnosis and prognosis of several human 
cancers, few cancer biomarkers have been identified in dogs, and none are currently used in 
veterinary clinical settings (60). Moreover, the use of cancer biomarkers in veterinary 
medicine has been recently challenged on the basis that the identified biological molecules do 
not reach the specificity, sensitivity, and accuracy required for routine clinical practice (61). 
According to Mukaratirwa (61), despite the advances in human oncology, human markers 
cannot be simply used as multiple species, or “bridging biomarkers” since the molecular 
etiology of most types of cancers varies from humans to dogs.  
Despite this criticism, other authors consider the pet dog population is an ideal model 
group for many diseases in humans, especially cancers (1, 62). Their large body size and 
similar metabolic rate make for easy translation of drugs and surgical techniques to the human 
population (62). Furthermore, they share a living environment with humans and are more 
closely genetically related to people than are mice (62). Compared to humans, dogs are a 
relatively inbred population; this may lend itself to successful identification of disease-causing 
genetic factors that are otherwise obscured in the human population (62). Finally, unlike 
mouse models, diseases in dogs are spontaneous and more likely to reflect similar human 
disease (1).  
 Just like in human medicine, there are several possible uses for cancer biomarkers in 
helping veterinary clinical management of patients with cancer. The properties of the 
biomarker and the eventual test used to measure it will dictate which application the marker is 
suitable for. These include cancer screening, diagnosis, prognosis, prediction of therapeutic 
response and monitoring effectiveness of therapy, determining tumor recurrence or remission, 
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or even targeted therapies.  
 In order to be considered as screening tests in human medicine, biomarkers need to 
meet two essential requirements: (1) they must be able to detect cancers at a sub-clinical state, 
and (2) early detection must contribute to the improvement of clinical outcome (63). By these 
standards, cancer screening in veterinary medicine is far from being a clinical reality. 
However, the obvious criticism could be opposed by the development of promising biomarker 
discovery tools such as transcriptomics (the study of RNA transcript expression), 
metabolomics (the study of metabolites), and proteomics (the study of protein expression) 
(63). With the help of these large-scale comprehensive studies, veterinary scientists were able 
to develop new candidate molecules that are presently being evaluated (17). According to 
preliminary results, the future development of cancer screening tests in veterinary oncology is 
likely to enhance the prevention of cancer-related deaths and to reduce the morbidity 
associated with advanced tumors.  
 A tumour marker used in diagnosis of cancer involves the same considerations as a 
biomarker for screening. Most markers identified to date in veterinary research, not 
surprisingly, have either low diagnostic sensitivity or specificity (61). Notwithstanding these 
limitations, for patients in high-risk groups where prevalence is relatively high, such as dog 
with lymphoma (27), using a diagnostic marker would aid in deciding whether more invasive 
tests are required. 
 Determining the prognosis of a tumour is essential in deciding the course of therapy to 
be taken. Most tumour markers used in human medicine are correlated with cancer prognosis 
and other prognostic indications such as tumour grade and staging (16). However, due to the 
well-known limitations of biomarkers, the clinical decision to determine a therapeutic course 
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of action cannot be taken based on the levels of the marker alone. However, the availability of 
such a biomarker in veterinary clinical practice would obviously help the oncologists to 
predict and monitor therapeutic response. This determines if the therapy was effective and also 
determines if there is tumour recurrence, as the biomarker level would be seen to increase 
again.  
 Finally, the advantage of actively researching for biomarkers in veterinary oncology, 
besides the obvious possible improvement in the remission rates and survival of the man’s best 
friend, resides in the idea that the dog might be a possible animal model for human NHL. In 
dogs, the tumors seem to progress more rapidly, thus permitting clinical trials to be completed 
quickly, thereby acting as a bridge to human clinical applications (1). Furthermore, the short 
remission interval followed by resistance to treatment offers the possibility to test novel 
antitumoral drugs (1). Many interesting markers currently under investigation have proved 
efficacious in canine lymphoma (64-66).  
The following sections of this thesis will focus on presenting the cancer biomarkers 
currently identified in the veterinary literature. Although, several publications address the need 
of advancing the study of cancer biomarkers, for now no ideal maker has been discovered for 
any canine tumor. As the progress in molecular techniques in oncology advances, so does the 
understanding of tumor biology, and more cancer biomarkers with better sensitivity and 
specificity will be found and used in clinical assay.   
 
3.1. Serum markers in veterinary medicine  
As in human medicine, measuring cancer biomarkers in bodily fluids has several 
advantaged such as easier sampling and handling, pain reduction in patients, and non-invasive 
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detection (17). These serum biomarkers have the potential to be beneficial not only for 
diagnostic of cancer, but also for monitoring the recurrence of tumors after surgical resection 
and the effect of anticancer drug therapies (67). Progressively, and with increasing rapidity, 
these prominent advantages have pushed the scientific community to the search for novel 
serum markers that could reliable be used in clinical settings. However, due to overlapping 
results, the data in not compelling enough to warrant routine use of these markers. The 
potential molecules are still not standardized and expensive for veterinary practice, thereby 
limited to preclinical exploratory research. 
The following table (Table 9) summaries the serum markers mentioned in the 
veterinary literature. Most of the molecules present elevated serum levels in several cancers, 
however, their low specificity remains the dispute subject of several articles.  
Table 9. Serum markers in veterinary medicine (68-72) 
Biomarker Type Condition Potential use Sample 
Serum Ferritin Protein  
Histiocytic 
Sarcoma 
Diagnosis Serum  
Alpha1-acid 
glycoprotein 
Protein 
Carcinoma, 
Sarcoma and 
Round cell tumors 
Diagnosis Serum  
CK19, 
ERBB2, 
CLDN7, ELF3 
Gene 
overexpression 
Mammary tumors 
Diagnosis, Prognosis, 
Treatment response  
Serum  
VEGF  Protein  
Several 
Aggressive canine 
tumors  
Diagnosis Serum  
Thymidine 
Kinase 1 
Protein Hemangiosarcoma Differential diagnosis Serum 
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3.1.1. Detection and monitoring of lymphoma using serum makers  
 Research regarding the use of serum markers for the detection and monitoring of 
lymphoma in dogs reveals few markers of interest. To date, the measurements of serum 
thymidine kinase 1 (TK1) in canine lymphoma is the most studied (23, 72). Published results 
suggest that TK1 could potentially be used in prognosis since its elevation may precede 
clinical recurrence in some cases (23). Besides TK1, a variety of other markers have been the 
object of preclinical studies, however, no conclusion can be drawn as of yet on their potential 
clinical use. The table below (Table 10) summarizes the molecular targets published to date in 
veterinary articles. 
Table 10. Lymphoma serum biomarkers detectable in dogs (23, 73-82) 
Biomarker Type Condition Potential use Sample 
Thymidine 
Kinase 1 
Protein Lymphoma 
Prognosis, Disease 
Monitoring  
Serum  
Serum C-reactive 
Protein 
Protein 
Multicentric 
Lymphoma, High 
Grade Lymphoma  
Prognosis Serum 
Lactate 
dehydrogenase 
Protein  Lymphoma Prognosis Serum  
   High-mobility 
group B1 proteins 
Protein Lymphoma 
Prognosis, Treatment 
outcome 
Serum 
Alpha-fetoprotein Protein 
Multicentric 
Lymphoma 
Prognosis, Staging  Serum 
VEGF Protein Lymphoma Prognosis Serum 
Cobalamin Vitamin 
Multicentric 
Lymphoma 
Prognosis Serum 
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3.2. Tumor markers in veterinary medicine  
Many proteins that could reflect the existence of the an early neoplastic process are not 
released or do not cross the cytoplasmic membrane of cancerous cells, making serum or 
plasma detection impossible (70). Moreover, the challenges in biomarker discovery using 
blood, is that plasma proteome is extensive, consisting not only of the indigenous proteins but   
also transient proteins which are secreted and shed into the bloodstream (83). The highly 
abundant proteins (i.e. albumin and IgG) make the low-abundant proteins that may serve as 
serum biomarkers difficult to identify (84). Consequently, the importance of using tumor 
markers in staging, prognosis, and treatment efficacy becomes evident.  
 In the past decade, the application of gene expression profiling (GEP) in tumors has 
contributed to the identification of unique gene expression signatures for major human 
cancers. Using GEP studies researchers have defined distinct molecular subtypes of different 
tumors (51, 52) that turn out to represent a significant difference in patient outcome following 
chemotherapy regiments.  
 In veterinary studies, GEP analysis in common canine cancers is currently underway, 
which, once complete, will allow the identification of informative expression signatures for 
several subtypes (85-87). To date, veterinary medicine lags years behind its human 
homologue, with only a handful of studies analyzing the specificity and sensitivity of tumor 
markers (Table 11). Although a few potential molecules have been identified, mainly for 
immunohistochemical study, there is yet no sufficient evidence to warrant their routine use in 
clinical practice (88).  
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3.2.1. Detection and monitoring of lymphoma using tumor markers  
 The research for lymphoma tumor markers in veterinary medicine proves to be 
challenging. A review of the literature reveals only one potential biomarker: P-glycoprotein. 
The expression of the protein on malignant lymphocytes has a negative association with 
remission and survival times (4). The mechanism surrounding this predictive characteristic of 
the molecule is closely related to the acquisition by the malignant cells of multiple drug 
resistance (MDR). Belonging to a family of transmembrane transporter proteins, P-
glycoprotein removes foreign molecules from the cell, reducing the effects of chemotherapy 
(4). Unfortunately, due to the fact that the development of MDR is not strictly related to the 
Table 11. Tumor biomarkers in veterinary medicine (61, 88-92) 
Biomarker Type Condition Potential use Sample 
BMP2, LTBP4, 
DERL 1  
Genes  
Mammary 
Tumors 
Malignancy diagnosis  Tissue  
HBME-1  Epitope  Ovarian Tumors Differential diagnosis Tissue 
c-KIT Gene 
Mast Cell 
Tumors 
Prognostic  Tissue 
Chondroitin 
sulfate 
proteoglycan - 4 
Proteoglycan Melanoma 
Immunotherapeutical 
target  
Tissue  
Ki-67 Protein 
Melanomas, Mast 
Cell Tumors 
Prognostic  Tissue 
Alpha-3 integrin Protein Melanoma 
Treatment (delivery of 
cytotoxic agents) 
Tissue 
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expression of the protein, the research on possible therapeutic applications of the marker was 
discontinued.  
In conclusion, despite tremendous potential value, the use of cancer biomarkers in 
veterinary oncology remains controversial at best. Potential canine biomarkers suffer from low 
sensitivity and/or specificity, limited applications and possible biases. Nevertheless, newly 
discovered biomarkers await validation and VCP is certainly one of them.  
 
Chapter 4: Valosin containing protein (VCP) as a cancer biomarker  
 
4.1. Structure of VCP 
 Valosin-containing protein (VCP), also known as p97/Cdc48 (S. cerevisae)/ter94 
(Drosophila), is an ubiquitous type II AAA+ (ATPase associated with various cellular 
activities) protein which is highly evolutionarily conserved among multiple species (93). This 
diverse family of enzymes is associated with a wide range of cellular processes including 
proteolysis, DNA repair and membrane fusion that it carries out in an ATP-dependent manner 
(94). By electron microscopy, VCP forms a hexameric stricture composed of two internal 
AAA domains (also referred to as the D1 and D2 domains), a C-terminal regulatory and 
binding domain, and an N-terminal cofactor and substrate-binding domain (Figure 1) (95). The 
D1 domain is the region primarily responsible for oligomerization of VCP monomers into 
homohexamers (Figure 1) (96). On the other hand, the ATPase activity conferred by the D2 
domain is essential for VCP’s function as a molecular chaperone in a plethora of distinct 
cellular processes (97). The predominant view of VCP’s structure-function relationship is that 
the large amount of energy released upon ATP hydrolysis by the ATPase activity-containing 
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D2 ring is transduced through the relatively fixed D1 ring to the substrate/cofactor-binding N-
domain (96). This motion has been described as a “ratchet-like” mechanism (96). 
 
 
 
Figure 1. Structure of the hexameric AAA+ protein VCP/p97. Each subunit consists of a 
globular N-terminal domain (green), the two AAA ATPase domains D1 (cyan) and D2 (blue), 
and a C-terminal tail (grey) D1 and D2 form two stacked hexameric rings. The N-terminal 
globular domain is positioned at the periphery of the D1 ring. 
 
Adapted from Mayer, Bug, & Bremer 2012. 
 
4.2. Role of VCP in the cell  
 The staggering variety of binding partners that VCP can interact with through both its 
N-domain and C-terminal domain allows for a wide and diverse array of cellular functions 
(95). The N-terminal domain binds both directly to poly-ubiquitin chains, as well as to adaptor 
proteins. Three core adaptors have been identified in the regulation of diverse cellular 
functions: NPL4-UFD1 (ubiquitin fusion degradation 1 – nuclear protein localization 4), 
UBXD1 (ubiquitin regulatory X domain 1) and p47 or NSFL1C (N-ethylmaleimide-sensitive 
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factor L 1 cofactor)  (Figure 2) (95). Two of these proteins that bind the N-terminus of VCP 
are p47, which contains a UBX (Ubiquitin regulatory X) domain and is involved in membrane 
fusion, and NLP4-UFD1, which contains a UBD (ubiquitin-fold domain) and is involved in 
proteasome targeting of substrates (95, 96). The C-terminal domain of VCP can bind proteins 
with various functions through the UBXD1 cofactor (95).  
 
Figure 2. VCP and its three core 
adaptors regulate diverse cellular 
functions. VCP homohexamer forms a 
barrel-like structure that mutually binds 
one of three core adaptor complexes, 
Npl4-Ufd1 heterodimer, UBXD1 or 
p47, and regulates diverse cellular 
functions as indicated in white boxes. 
ERAD, endoplasmic reticulum-
associated degradation; RAD, 
ribosomal-associated degradation; 
CAD, chromatin-associated 
degradation. 
 
Adapted from Vaz, Halder, & Ramadan 2013  
 
 VCP coordinates a number of ubiquitin-regulated processes through its basic function 
as a molecular segregase that utilizes ATP-powered conformational changes in the assembly 
and disassembly of macromolecular machineries (Figure 3) (98). VCP is essential to some 
aspects of ubiquitin-dependent degradation including endoplasmic reticulum-associated 
degradation (ERAD), degradation of some cytosolic proteins by the ubiquitin-fusion domain 
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(UFD) pathway and delivery of substrates to the proteasome, and rapid maturation of 
autophagosomes. VCP also is integral to some non-proteolytic aspects of ubiquitin signalling, 
including chromatin decondensation following mitosis, nuclear envelope assembly, DNA 
replication and repair, and post-mitotic Golgi reassembly (95, 99, 100).  
 
 
 
Figure 3. Multiple functions of VCP. N-terminal cofactors involved in each function are also 
indicated. Functions shown in yellow are related to membrane reformations. Functions shown 
in blue pertain to protein degradation. Functions shown in green pertain to protein 
aggregation. Functions shown in pink functions are key to cell cycle and DNA replication.  
 
Adapted from Yamanaka, Sasagawa, & Ogura 2012.  
 
	   VCP is essential for ERAD, a process in which defective or abnormally folded ER 
proteins are degraded (99). As with many other functions, VCP’s participation in ERAD is 
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dependent on one specific cofactor, NPL4-UFD1 (95). Specifically, substrates destined for 
proteasomal degradation are translocated from the ER lumen to its cytosolic face where they 
are bound by the VCP/ NPL4-UFD1 complex (95). The ERAD substrates are subsequently 
ubiquitinated and transferred to the proteasome for degradation (99). 
 While a large amount of work done regarding VCP’s role in protein turnover has 
focused on ERAD, a role for VCP in cytosolic protein degradation has also been outlined (98, 
99, 101, 102). As support for this role, VCP has also been shown to be required for the 
ubiquitin-independent proteasomal degradation of some proteins (103). There is not yet a 
consensus mechanism for VCP’s role in cytosolic protein turnover, being described 
interchangeably as a scaffold, shuttling factor, or segregase of ubiquitinated proteins (100). It 
is likely to play all of these roles depending on both the substrate protein as well as the 
cofactors bound to VCP (97). 
 VCP has more recently been implicated in the autophagic process as well, and seems to 
be required specifically for the maturation of the autophagosomes into autolysosomes (97). 
The protein also facilitates the proteasome-independent degradation in the lysosome (97). 
Through a gear box-like function, it controls protein sorting in the endocytic pathway and 
autophagy (96). Finally, VCP protects the cell from protein induced stress by degrading or 
recycling unwanted proteins and protein aggregates situated in the outer mitochondrial 
membrane and cytosol (96).  
 Direct evidence links VCP with genome stability (95). Intentional VCP inactivation 
slows the progression of the cellular cycle through anaphase and, in some cases, even the 
discontinuation of mitosis (96). This phenomenon is explained by the VCP’s role in removing 
and/or degrading cellular cycle related proteins, regulating DNA replication, assuring proper 
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chromosome alignment, segregation, decondensation and nuclear envelope formation (95). 
The hypothesis linking VCP and genome stability is further supported by the direct control the 
protein has on the gap-filling DNA synthesis after UV damage (95). These activities prevent 
the accumulation of ubiquitinated substrates on the chromatin, and consequently the 
appearance of PICHROS (protein-induced chromatin stress) and genome instability, 
intracellular processes characteristic of cancer development (95).  
 
 
Figure 4. Protein-induced chromatin stress (PICHROS). Inactivation of VCP causes the 
accumulation of polyubiquitinated substrates on chromatin, causing PICHROS that inhibits 
essential DNA metabolic processes, such as DNA replication, transcription, or DNA repair, 
and leads to genome instability. 
 
Adapted from Vaz, Halder, & Ramadan 2013  
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 The functions of VCP and its adaptor complexes described here are only a few of the 
better-characterized functions of VCP. It is clear though that the binding of the cofactors to 
VCP determines its diverse cellular functions in all compartments of the cell. Despite knowing 
the identity of over 40 adaptors, the association between VCP and such a wide range of 
proteins is still poorly understood.  
 
4.3. VCP as cancer biomarker in human medicine 
 The diversity of VCP functions within the cell implicates the protein in a possible large 
number of diseases, especially related to protein quality control, offering a potentially 
interesting biomarker and/or therapeutic target.  VCP has been associated with various 
neurodegenerative disorders (104). These include senile plaques in Alzheimer’s disease, Lewy 
bodies in Parkinson’s disease, neuronal intranuclear inclusions in polyglutamine diseases, and 
ubiquitin-positive inclusions in amyotrphic lateral sclerosis (ALS) (104, 105). In pathology 
studies, VCP has been shown to localize with nuclear inclusions in Huntington and Machado-
Joseph disease (104). Most interestingly, the disorder Inclusion Body Myopathy and Paget’s 
disease of the bone and Frontotemporal Dementia (IBMPFD) has been linked to various 
mutations of the VCP gene (104).  
 Prior to the recognition that mutations in VCP were causative of neurodegenerative 
disorders, VCP was implicated as playing a role in cancer. VCP has been found overexpressed 
in several human carcinomas (93, 100). Furthermore, RNA interference or inhibition of VCP 
in tumor cell lines has been shown to cause cell death (106-108). Although there is no 
evidence that mutations of VCP are related to cancer, the involvement of the molecule in 
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genome stability, protein degradation, and cell cycle has led scientists to speculate that cancer 
relies on intact VCP functions (95, 109-111), rendering the protein a potential highly sensitive 
cancer biomarker.  
 
4.3.1. VCP as a tumor marker 
 There is a small but increasing number of studies focusing on the association between 
VCP overexpression in tumor tissue and the development of several human carcinomas.  Most 
of the recent attention in the preclinical setting has been focused on the predictive nature of 
VCP and its significance as a tumor maker. One group, Yamamoto et al., examined between 
2003 and 2004 in a series of 9 studies the expression levels of VCP in different human 
carcinomas (112-120). The authors reported that VCP overexpression, as determined by 
immunohistochemistry, is a useful marker for predicting tumor extension, lymph node 
metastasis, and prognosis of esophageal carcinoma (112), non-small-cell lung carcinoma 
(113), pancreatic ductal adenocarcinoma (114), colorectal carcinoma (115), gastric carcinoma 
(116), gingival squamous cell carcinoma (117), pancreatic endocrine carcinomas (118), 
hepatocellular carcinoma (119), and follicular thyroid cancer (120). The authors further 
propose that besides predicting patient prognosis VCP might also provide a novel way to 
explore effective treatment modalities for the mentioned malignancies. In addition and as 
validation that VCP is associated with metastasis and prognosis, another group, Tsujimoto et 
al., came to the same conclusions when studying VCP expression in prostate cancer (18). 
 Interestingly and of importance for this thesis, one recent study has investigated the 
expression levels of VCP in primary orbital MALT lymphoma, a type of NHL (121). Zhu et 
al. observed that VCP could be a useful tumor marker for predicting the prognosis of this sub-
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type of lymphoma, since the 5-year disease-free and overall survival rate of patients with 
lower VCP expression levels was significantly better than that of higher expression levels 
(121). Significantly, VCP levels were correlated with recurrence and tumor size (121).  
 While there are no clinical tests that use VCP as a prognostic biomarker for human 
cancers, the emerging field of tumor markers is undoubtedly progressing and the vast body of 
knowledge from basic science and pre-clinical work is reassuring. Moreover, these results 
make a strong case for the effectiveness of VCP as a tumor marker for several human cancers.  
 
4.3.2. VCP as a serum marker 
 Despite the great potential shown by VCP as a tumor marker, there has been only one 
study measuring the overexpression of the protein in sera of cancer patients. In an experiment 
designed to identify novel serum diagnostic markers for human ovarian granulosa cell tumor 
(GCT), Laguë et al., detected using proteomic profiling by mass spectrometry elevated VCP 
levels in the preoperative serum of GCT patients (17). Motivated by these results, the authors 
decided to determine the specificity of VCP in sera of patients with ovarian, breast, colon, 
pancreatic, lung, and prostate cancer, and, again of interest to us, NHL (17). Interestingly, 
increased serum VCP levels were observed in all malignancies with the exception of lung and 
prostate cancer (17). The results obtained by Laguë et al. in 2012 argued for the potential use 
of VCP as a sensitive serum marker for NHL, forming the basis for the present study.  
 
4.4. VCP as cancer biomarker in veterinary medicine  
 In veterinary studies, cancer biomarker analysis in common canine 
malignancies is currently underway, which, once complete, will allow the identification of 
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promising makers and development of clinically applicable tests. Although several different 
studies in human malignancies have identified VCP as a promising serum and tumor 
biomarker, being useful for the detection of a variety of neoplastic diseases including NHL, at 
the initiation of this research there was no study investigating VCP as a potential cancer 
biomarker in veterinary medicine. With knowledge generated by the previous studies, this 
thesis is the first to evaluate VCP as a cancer biomarker for canine lymphoma. 
  
 
Hypothesis and objectives  
 Several molecular products metabolized and secreted by neoplastic tissue could be 
characterized biochemically in cells, tumor tissues and/or body fluids. They may act as cancer 
biomarkers, useful as indicators of tumor stage and grade as well as for monitoring responses 
to treatment and predicting recurrence. Few studies have focused on investigating the potential 
of such markers in veterinary medicine. These molecules could be used to aid in the diagnosis 
and determining the prognosis of canine lymphoma, which represents one of the most 
prevalent types of cancers in dogs. Among these proteins, VCP has been described as 
significantly increased both in sera and tumor tissue of several human carcinomas. Giving that 
the molecular and genetic processes that drive cancer development in humans and other 
mammals are highly related, we hypothesize that VCP will be significantly increased in sera 
and tumor tissue of dogs with lymphoma compared to healthy dogs. Moreover we hypothesize 
that VCP levels will vary according to the tumour’s grade, being highest in high-grade 
lymphomas. 
 In order to test this hypothesis, this study’s objectives were to: 
 1. Evaluate the expression of VCP in canine lymphoma compared to normal lymph 
      nodes and also to see if this expression differs among different tumor types and 
      grades 
 2. Determine if VCP could be useful serum and tumor biomarker in canine lymphoma 
 3. Determine any potential correlation between tumor and serum VCP expression in 
      canine lymphoma. 
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ABSTRACT  
 
 Although routinely used for diagnosis, prognosis, treatment monitoring, and recurrence 
of several human cancers, few cancer biomarkers have been identified in dogs, and none are 
currently used in the veterinary clinical setting. Valosin containing protein (VCP), an essential 
biochemical component of a wide-range of ubiquitin-linked cell biological reactions, was 
recently identified as a potential promising cancer biomarker. Given that the molecular and 
genetic processes driving lymphoma’s development in humans and dogs share many 
similarities, we hypothesize that VCP will be significantly increased in sera and tumor tissue 
of dogs with lymphoma, more specifically in high-grade tumors, compared to healthy dogs. 
VCP expression was determined by immunohistochemistry in formalin-fixed tissues from 
healthy and cancer-bearing dogs. Canine lymphoma cell lines CLBL1, 17-71 and CL1, 
peripheral blood mononuclear cells (PBMCs), and sera VCP were determined by 
immunoblotting and signal was quantified by densitometry. Increased VCP levels were 
observed in tumor tissue of dogs with high-grade B-cell lymphomas compared to low-grade 
tumors (P < 0.05). Furthermore, we observed a corresponding accumulation of the protein in 
tumor cell line compared to PBMCs (P < 0.05). Conversely, no significant difference was 
found in the VCP expression in the sera of dogs with lymphoma compared to healthy controls. 
Together, these results suggest that VCP positively correlates with malignancy in canine B-
cell lymphomas. This study represents an important step towards providing veterinary 
oncologists with a simple but effective prognosis tool for canine B-cell lymphoma.  
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INTRODUCTION 
 
 Recent development of veterinary care has led to a significant extension of dogs' 
lifespan and allowed the diagnosis and treatment of a growing number of different diseases in 
this species (1). Unfortunately, among all diseases in dogs, cancer is considered the main 
cause of mortality, with lymphoproliferative disorders accounting for up to 30% of all canine 
cancers (2). As in humans, the heterogeneous disease is one of the most common dog 
neoplasms with an incidence of more than 33 cases per 100 000 dogs per year (3-5). Unlike 
humans, multicentric lymphoma accounts for 80% to 85% of reported cases, and diffuse large 
B-cell lymphoma is the most common histomorphologic variant (6). Moreover, due to the 
rapid course of the disease and lack of both baseline and follow-up medical examinations (7), 
our canine patients are still diagnosed late in the course of their disease. This represents a 
major limitation to the success of our therapies, but more notably highlights the importance of 
identifying better tools to assist veterinarians in the early diagnosis of this insidious disease.  
 Classically, the diagnosis of canine lymphoma was dependent on morphologic 
characteristics established by cytology and/or histopathology (8). In the past decade, much 
research has been turned toward additional assays such as immunocytochemistry, 
immunohistochemistry, flow cytometry, and PRC to detect clonal antigen receptor gene 
rearrangement (8). However, the diagnostic tests are only truly useful when the tumor can be 
biopsied, in many cases when the disease is well advanced. It would be extremely valuable for 
clinicians to detect, stage, monitor and evaluate cancer’s recurrence for risk group 
stratification, effective treatment intervention and outcome prediction at an early stage of the 
disease (9, 10).  
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 Although routinely used for diagnosis, prognosis, treatment monitoring, and recurrence 
of several human cancers, few cancer biomarkers have been identified in dogs, and none are 
currently used in the veterinary clinical setting (11). Historically, human oncological research 
has focused its attention on two distinct categories of cancer biomarkers: serum and tumor 
markers. Serum makers have considerable value for clinical screening, diagnosis, and follow-
up (12). On the other hand, tumors markers give valuable insight in the development of the 
disease by helping clinicians, stage, prognosticate, monitor treatment efficacy, and/or evaluate 
cancer recurrence (9). For veterinary oncology, the identification of both new serum and 
tumor biomarkers would prove a valuable tool for the fight against lymphoma.  
 A review of the veterinary literature with regards to the use of cancer makers reveals 
few markers of interest. To date, the measurement of serum markers in canine lymphoma had 
focused for the most part on serum thymidine kinase 1 (TK1) (13-16). The results published 
suggest that TK1 is prognostic and that its elevation could precede clinical recurrence in some 
cases (13). A variety of other markers have been studied, including several inflammatory 
proteins (17-21), alpha-fetoprotein (22-24), alkaline phosphatase (25, 26), lactate 
dehydrogenase (27, 28), and plasma DNA (29). However, no conclusions can be drawn yet on 
their potential clinical use based on the results on these studies. Moreover, the search for 
tumor markers is even more challenging, with only one studied target: P-glycoprotein (30). 
Despite their tremendous potential value, the use of cancer biomarkers in veterinary oncology 
therefore remains in its infancy, and awaits identification of a sensitive and specific lymphoma 
marker to become clinically applicable.  
 Using a translational proteomics approach, Lagüe et al have identified in several 
human cancers, including Non-Hodgkin’s Lymphoma (NHL), a new promising serum 
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biomarker, valosin containing protein (VCP) (12). VCP proved to be a highly sensitive 
marker, being often increased in cancer patients who did not otherwise display increased 
levels of the “gold standard” serum markers for their cancer type (12). Furthermore, a growing 
body of research suggests that VCP expression correlates with prognosis in a range of human 
malignant tumors (31-37), making the protein a possible major target in the development of 
the next generation of cancer biomarkers.  
 The ubiquitously expressed VCP (also known as p97) is a prominent member of the 
highly conserved AAA+ proteins, which are known for their various cellular and molecular 
chaperone activities (38). VCP is an essential biochemical component of a wide-range of 
ubiquitin-linked cell biological processes, including the ubiquitin-dependent proteasome 
degradation pathway, Golgi, endoplasmatic reticulum (ER), and nuclear membrane 
reassembly, ER associated degradation (ERAD), cell cycle regulation and DNA repair (39-
43). Within these processes, VCP acts as a molecular segregase by binding to distinct cofactor 
proteins and utilizes ATP-powered conformational changes in the assembly and disassembly 
of macromolecular machineries (44-46). Due to its participation in a remarkable number of 
vital cell biological processes, mutations in VCP have been linked with accumulation of 
misfolded, polyubiquitinated proteins that endanger the cell’s viability and lead inevitably to 
apoptosis (47-49). Not surprisingly, a few studies have reported elevated levels of VCP in 
several human malignancies (12, 31-37) and this is most likely due to protein induced 
chromatin stress (PICHROS) (50) and protein damage-induced stress signals that are elevated 
in cancer cells (51). Having a high proliferative and metabolic rate, malignant cells seem more 
dependent on VCP for the clearance of abundant, misfolded, aggregate-prone, and potentially 
toxic proteins, stabilizing their genome and facilitating their survival (51).  
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 Given that the molecular and genetic processes that drive lymphoproliferative cancers   
development in humans and dogs share many similarities (52-54), we hypothesize that VCP 
will be significantly increased in sera and tumor tissue of dogs with lymphoma compared to 
healthy dogs. We also hypothesize that VCP levels will vary according to the tumour’s grade, 
rendering VCP measurements more useful for lymphomas with a high mitotic rate and 
significant necrosis. Our specific objectives are to: 1) study the expression of VCP in canine 
lymphoma and normal lymphoid tissue; 2) determine if VCP may be useful as a serum and 
tumor biomarker in canine lymphoma; and 3) determine any potential correlation between 
tumor and serum VCP expression in canine lymphoma.  
 
MATERIALS AND METHODS  
 
Lymphoma Tumor Samples and Cell Lines  
  Frozen and formalin-fixed lymphomas tumor samples and sera used for western 
blotting and immunohistochemistry were obtained from the Canine Comparative Oncology 
and Genomics Consortium (CCOGC) and from the Oncology Service at the Faculté de 
Médecine Vétérinaire, Université de Montréal. Tumor grades and phenotype were determined 
using the classification system established by Valli et al (55) by a board-certified veterinary 
pathologist.  Healthy lymph nodes used as controls were obtained from cadavers of healthy 
dogs euthanized for reasons unrelated to illness, and were obtained from the Département de 
Pathologie et de Microbiologie, Faculté de Médecine Vétérinaire, Université de Montréal.  All 
lymph nodes were aseptically removed during autopsy. A portion of the node was placed in 
formalin for the purpose of histopathological evaluation. The remainder of the lymph node 
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was trimmed to remove the capsule, connective tissue, and adipose tissue; placed in a 
Falcon™ 15 mL high-clarity polypropylene conical centrifuge tube and stored at -800C until 
processed.  
 The lymphoma cell lines used in this study (CL-1, 17-71, CLBL-1) were previously 
characterized and were cultured as described in Seiser et al. and Rütgen et al. (56, 57). Dr. 
Steven Sutter (North Carolina State University) provided the 17-71 and CL-1 cell lines and 
Dr. Barbara Rütgen (Central Laboratory, Department of Pathobiology, University of 
Veterinary Medicine Vienna) the CLBL-1 cell line. The cell lines were cultured in T75 flasks 
using cell media containing either 10% (CL-1 and 17-71) or 20% (CLBL-1) heat inactivated 
fetal bovine serum, RPMI, and 100 units/ml of penicillin, 100 µg/ml of streptomycin and 0.25 
µg/ml of fungizone (Invitrogen, catalog numbers 12483-020, 61870-036, 15240-062, 
respectively). The cells were incubated at 37°C in humidified 5% CO2/95% air.  
 Peripheral blood mononuclear cells (PBMCs) were obtained from clinically healthy 
dogs (n=5) by venipuncture and isolated using Histopaque-1077 (Sigma-Aldrich, St. Louis, 
MO), as directed by the manufacturer. Briefly, whole blood was collected in 5ml heparinized 
tubes, layered on an equal volume of histopaque-1077 and centrifuged at 400g for 30 minutes 
for the recovery of mononuclear cells.  PBMCs were cultured under the aforementioned 
conditions as CL-1 and 17-71 cells. All animal procedures were approved by the Institutional 
Animal Care and Use Committee of the Université de Montréal and conformed to the 
Canadian Council on Animal Care (CCAC) Policy on Humane Care and Use of Laboratory 
Animals. 
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Immunohistochemistry  
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded, 3 µm 
lymphoma and normal lymph node sections using the VectaStain Elite Avidin-Biotin Complex 
Kit (Vector Laboratories, Inc., Burlingame, CA) as directed by the manufacturer.  Sections 
were deparaffinized and probed with Anti-VCP [5] mouse monoclonal antibody (Abcam Inc., 
Cambridge, MA, catalog number ab11433) as directed by the manufacturer, except blocking 
was done with 5% normal serum in TBST for 1 hour at room temperature and incubation with 
the secondary antibody (biotinylated anti-mouse reagent, Vector Laboratories, Inc., dilution 
1:500) was done for 30 minutes.  Staining was done using 3,3’-diaminobenzidine peroxidase 
substrate kit (Vector Laboratories, Inc.) as directed by the manufacturer. Negative controls 
were prepared using the primary antibody described above that was pre-incubated for one hour 
at room temperature with VCP peptide (792-806, Abcam Inc., catalog number ab39788) in a 
1:10 antibody:peptide ratio. Sections were counterstained with hematoxylin prior to mounting.  
In order to evaluate the staining intensity distribution of VCP, four regions per slide 
(n=4 slides per tumor phenotype and grade) were selected at random and photos were taken at 
a 63x magnification. From these photos, a smaller field containing approximately 100 cells 
was selected at random and used for analysis. VCP expression on each slide was placed into 
four categories, 0 (negative), 1 (low), 2 (intermediate), and 3 (high), based on the scoring 
results for the level of nuclear and cytoplasmic staining. All slides were reviewed by two 
separate evaluators and a board certified pathologist, all blinded with regards to the phenotype 
and grade of the tumor. The grading system was inspired by Steinhardt, et al 2009 (58).  
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Images were taken using Axio Imager M.1 microscope (Zeiss), analyzed, and 
processed using Zen 2012 Digital Imaging for Light Microscopy software (Zeiss).  
 
Western Blot Analysis 
Lymphoma tumor samples, healthy lymph nodes, lymphoma cell lines, PBMCs and 
sera were used for western blot analysis.  Lymphoma cell lines and PBMCs protein extracts 
were obtained using M-PER® Tissue Protein Extraction Reagent and Halt Protease and 
Phosphatase Inhibitor Single-Use Cocktail (Thermo Fisher Scientific, Rockford, IL, catalog 
numbers 78510 and 78442, respectively) as described by the manufacturer.  Lymphoma 
tumors and healthy lymph node protein extracts were obtained using RIPA buffer, PhosSTOP 
Phosphatase Inhibitor Cocktail Tablet and Complete Mini Protease Inhibitor Cocktail Tablet 
(Roche Diagnostics, Indianapolis, IN, catalog numbers 04906845001 and 11836153001, 
respectively). Protein concentrations were quantified using the Bradford method (BIO-RAD 
Protein Assay, 500-0006).  Samples (18µg) were resolved on a 10% sodium dodecyl sulfate-
polyacrylamide gels and transferred to Hybond-P PVDF Membrane (GE Amersham, 
Piscataway, NJ).  Blots were then probed at 4oC overnight with primary antibody against VCP 
[5] mouse monoclonal antibody (Abcam Inc., Cambridge, MA, catalog number ab11433), 
Ubiquitin Lys48-Specific clone Apu2 (Millipore, Temecula, CA, catalog number 05-1307), 
and ACTB (C4) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, catalog number sc-47778) 
as directed by the manufacturers. ACTB was used as the loading control. The blots were 
incubated for 1 hour at room temperature with horseradish peroxidase-conjugated secondary 
anti-mouse and anti-rabbit IgG antibodies (Promega, Madison, WI, catalog numbers W4021 
and W4011, respectively), and then Immobilon Western Chemiluminescent HRP Substrate 
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(Millipore, catalog number WBKLS0500) was used to visualize the protein bands with Bio-
Rad ChemiDocTM MP imaging system (Bio-Rad Laboratories, Hercules, CA). To quantify the 
specific band intensity for further statistical analysis the software Image LabTM 5.0 (Bio-Rad, 
Imaging software) was also employed.  
 
Statistical methods 
A ROC curve was performed on Western blotting data in order to establish the optimal cut-off 
value that would define high vs low VCP expression levels. K-48 polyubiquitinated protein 
and VCP expression in tumor and sera were analyzed by one-way ANOVA with Tukey's 
multiple comparisons test to identify differences between specific groups and an unpaired t 
test with Welch’s correction for the VCP expression in PBMCs and lymphomas cell lines. 
Data were log-transformed if variances were significantly different between samples. Data are 
presented as means ± SEM. Differences were considered significant when P < 0.05. Analyses 
were done using Prism 6.0 software (GraphPad Software, Inc., San Diego, CA).  
 
RESULTS 
 
VCP protein expression correlates with malignancy in canine B-cell lymphomas.  
 To study VCP expression in canine lymphomas, 22 B-cell and 18 T-cell tumors were 
analyzed by immunoblotting and compared to normal lymph nodes. VCP levels in low-grade 
B-cell lymphomas were found to be similar to normal lymph nodes. However with a reference 
value for VCP levels set by the low-grade tumor’s immunoblotting band intensity, we 
observed that dogs with high-grade B-cell lymphomas displayed significant (P < 0.05) 
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increased levels of the protein (Figure 1A, 1C). Marginally increased levels of VCP were 
observed in the intermediate-grade B-cell lymphoma tumors compared to normal tissue, 
however the differences were not statistically significant (Figure 1A). VCP expression was 
also studied by immunohistochemical staining of 19 B-cell lymphomas slides (5 low-grade, 6 
intermediate-grade, 8 high-grade) and 4 normal lymph nodes. This furthered showed that low-
grade B-cell lymphomas express VCP at a level comparable to transient B-cells present in the 
mantle of lymphoid follicles, whereas VCP expression in intermediate and high-grade B cell 
lymphomas was more comparable to that found in maturing B-cells in germinal centers 
(Figure 2A-B). On the other hand, VCP expression in T-cell lymphomas did not show any 
significant pattern that would correlate with the grade of the tumor (Figure 1B). 
Immunohistochemistry performed on 15 T-cell lymphomas (3 low-grade, 5 intermediate-
grade, 7 high-grade) appeared with almost the same staining pattern, grade confounded, and 
lesser staining intensity compared to intermediate and high B-cell tumors (Figure 2C).  
 
VCP expression in PBMCs and canine lymphoma cell lines (CLBL-1, 17-71, CL-1) 
 We further used immunoblotting to compared the expression of VCP in 3 canine 
lymphoma cell lines to PMBCs. Analyses included the B-cell lymphoma-derived lines CLBL-
1 and 17-71, and the T-cell lymphoma line CL-1. A significant increase (P < 0.05) in VCP 
expression was associated with the lymphomas cell lines compared to PBMCs (Figure 3A).  
Moreover, the protein was expressed at high levels in each cell line individually when 
compared to the blood isolated normal cells (Figure 3B). 
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K-48 polyubiquitinated protein expression in canine lymphomas 
 To determine if the variations of VCP protein expression within B-cell or T-cell tumors 
affect the levels of polyubiquitinated proteins within the cell, immunoblotting was done using 
21 B-cell lymphomas and 18 T-cell lymphomas. Surprisingly, it was found that the differences 
were not statistically significant (P > 0.05) when compared between types, grades or to normal 
lymph nodes (Figure 4A-B). Increased VCP expression in intermediate and high-grade B-cell 
lymphomas therefore did not coincide with an expected decrease in K-48 polyubiquitinated 
protein.  
 
Serum VCP protein expression in canine lymphomas  
 To assess serum VCP protein expression in canine lymphomas, sera from 22 healthy 
dogs were compared by immunoblotting with 20 B-cell and 18 T-cell lymphomas diagnosed 
animals. Analyses of immunoblot band intensity found VCP expression to be marginally 
increased in the sera of some dogs with cancer compared to healthy subjects, however the 
differences were not statistically significant (P > 0.05) (Figure 5). In addition, we further 
investigated any potential correlation between VCP expression levels in sera versus tumors 
(not shown). However, no correlation was detected (r=0.062). 
 
DISCUSSION  
 
 VCP seems to be a cancer biomarker of interest in human oncology with several 
studies examining its expression in numerous types of tumor tissues and sera of cancer 
patients (12, 31-37, 59-62). A recent study has also indicated that VCP expression may be an 
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independent prognostic factor for the overall survival and disease recurrence in primary orbital 
MALT lymphoma, a type of B-cell lymphoma (37). In veterinary medicine, there are no 
published studies on VCP expression in lymphoma tissue, or any other cancer for that matter, 
and to our knowledge no publications exist on the expression of the protein in sera of dogs 
with lymphoma. In this report, we verified elevated VCP protein expression in canine 
lymphomas and we are the first to show that VCP is overexpressed in B-cell lymphomas, 
specifically in high-grade tumors. It remains to be determined if this increase in the protein’s 
levels is a cause or a consequence of tumor development, what the biological significance 
might be, and what its relatedness might be to the tumors’ grade. Additional analyses will 
therefore be required to answer these questions. It should however be noted that since VCP is 
involved in cancer cell proliferation and metastasis (63), indicating that it plays a crucial role 
for cancer biology, this could be an indication malignant B cell lymphomas require elevated 
levels of VCP to reduce PICHROS (protein induced chromatin stress) thus avoiding apoptosis. 
The exact mechanism of how malignant B-cell would produces such a high tension on their 
chromatin is unknown, but a possible explanation might be simply related to the higher growth 
rate and accumulation of genetic mutations specific to cancer cells (64). This would be 
entirely consistent with our finding that VCP expression in high-grade B-cell tumors is 
comparable to that found in the germinal centers of lymph nodes, where B-cells have a higher 
proliferation rate (65). Furthermore, low grade B-cell lymphomas, being characterized as 
slow-growing tumors, had, in immunohistochemistry trials, VCP levels comparable to those 
found in the mantle of lymph nodes, where cells are more differentiated and less proliferative 
(66). It therefore seems reasonable to propose that the increased VCP expression that we 
observed in B-cell lymphomas could be reflective of both malignancy and proliferative 
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activity, making VCP a potentially clinically useful tool for predicting tumor recurrence and 
patient prognosis.   
 Motivated by the increased values of VCP expression in high-grade B-cell tumors, we 
have carried out an experiment to measure its expression in PBMCs and cancerous cell lines 
17-71, CLBL1, CL1. This finding confirms and adds to our previous discovery, as the B-cell 
lymphoma cell lines, 17-71 and CLBL1 had increased VCP expression than normal blood 
mononuclear cells. Corroborated with the previous argument, this may indicated that 
malignant cells are dependent on VCP overexpression, making this protein a potential 
pharmaceutical target in treating lymphoma in dogs.  
 Despite our expectations, we found that there was no correlational pattern between the 
accumulation of K-48 polyubiquitinated proteins and tumor’s grade. The western blot analysis 
revealed, surprisingly, statistically insignificant levels of polyubiquitinated proteins in all 
lymphoma types. However, taking in account that cancerous cells, compared to their normal 
counterparts, have a higher mitotic rate (64), making them more prone for DNA damage and 
misfolded protein accumulation (REF), an accumulation of “signaled for degradation” proteins 
should have been observed in high-grade tumors where cellular division is significant. This 
finding suggest that high-grade B-cell lymphoma cells are likely react to an increase in 
polyubiquitinated proteins, associated with increased proliferative related mutations, by up-
regulating VCP expression. Due to the role VCP has in the maturation of autophagic vesicles 
and in the ERAD (67, 68), the two major systems for protein elimination, the degradation of 
proteins is accelerated, returning them to a level that is comparable to that found in lower-
grade tumors and normal cells. To answer these questions, addition work will be required in 
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order to make a clear correlation between VCP’s overexpression and the decrease in 
polyubiquitinated proteins in cancerous cells.  
 Unexpectedly, we failed to identify any relevant increase of VCP protein in the sera of 
dogs with lymphoma, and also failed to identify a correlation between serum and tissue levels 
of VCP in canine lymphomas. This is in contrast to the study of Laguë et al where VCP serum 
levels were significantly increased in human patients with NHL (12). It is often the case that 
there is no correlation between protein expression in cancer tissue and circulating levels of the 
protein (69). The reason for this observation is possibly due to the impossibility of the protein 
to access the circulating system or just a simple matter of dilution. Perhaps the VCP 
production by tumor cells in the selected dogs for this study was not strong enough to give 
significant western blot detection. Moreover, our analysis were limited by the relatively small 
sample size available, however it should be noted that there is a possibility that VCP’s 
expression pattern in human lymphoma is different than in its canine counterpart. Further 
experiments will be required to explore these novel theories. 
 In this study, the VCP expression levels were analyzed by western blotting and 
immunohistochemistry. We reported a clear correlation between VCP expression and canine 
B-cell lymphomas of high-grade. Moreover, using either one or both methods, several studies 
have reported the same positive correlation in hepatocellular carcinoma (35), gastric 
carcinoma (34), gingival squamous cell carcinoma (61), esophageal carcinoma (60) and 
several other human cancers (12, 31-33, 36, 59, 62) . Taken together with the other results, this 
shows the reliability of immunohistochemical and western blot method for the evaluation of 
VCP in canine malignancies.  
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 In summary this study shows for the first time that VCP expression, as determined by 
western blot and immunohistochemistry, is a new malignancy marker for canine high-grade B-
cell lymphoma. This represents the first step towards establishing VCP as a valuable clinical 
tool for diagnosis, predicting tumor recurrence and prognosis, which could eventually apply to 
the stratification of dogs with lymphoma for standardized treatment protocol. Based on our 
results, we conclude that VCP expression positively correlates with malignancy in canine B-
cell lymphomas and might represent a novel way to explore effective treatment modalities for 
lymphoid malignancies. 
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FIGURE LEGENDS 
 
Figure 1. VCP protein expression in canine lymphoma tumors. A) Analysis of the levels of 
VCP in low (n=6), intermediate (n=7), and high-grade (n=9) B-cell lymphoma tumors by 
western blot. Data are shown as means (columns) ± SEM (error bars). The results showed that 
the level of VCP is increased in high-grade tumors compared to low grade ones: *:P<0.05. B) 
Using the same method, we further examined the expression of VCP in low (n=4), 
intermediate (n=5), high (n=9) T-cell lymphomas tumors. Data are shown as means (columns) 
± SEM (error bars). No significant statistical difference was recorded: P>0.05. C) 
Representative western blot images form the analyses done in A and B. The first two lanes 
represent the levels of VCP in normal lymph nodes, followed by the expression levels of the 
protein in B-cell and T-cell lymphomas. β-Actin (ACTB) was used as a loading control.  
 
Figure 2. Western blotting analysis of VCP in PBMCs and lymphoma cell lines (17-71, 
CL-1, and CLBL-1). A) Detection of the expression of VCP in PBMCs (n=7), used as 
control, and canine lymphoid tumor cell lines (n=3). Data are shown as means (columns) ± 
SEM (error bars). Significant difference from control (P<0.05) is indicated with and asterisk 
(*). B) Western blot showing that the lymphoma cell line demonstrated markedly increase 
VCP expression levels compared to control PBMCs. β-Actin (ACTB) was used as a loading 
control.  
 
Figure 3. Immunohistochemical analysis of VCP expression in B-cell and T-cell 
lymphomas compared to lymph nodes . A) Photomicrograph of a normal lymph node 
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expressing different levels of VCP in the germinal center compared to the mantle. The dotted 
line delineates the two histological areas. B) Sections from representative low, intermediate, 
and high-grade B-cell lymphoma tumors. Note positive correlation of the increasing staining 
pattern with the tumor grade. C) Sections from representative T-cell tumors, exhibiting weak 
VCP staining and no significant increase in the protein levels among the low, intermediate, or 
high grades. Original magnification, 400X (A-C).  
 
Figure 4. K-48 Polyubiquitinated protein expression in canine lymphomas tumors. A), B) 
Western blot analysis of the expression levels of K-48 polyubiquitinated protein in low (n=6), 
intermediate (n=6), and high-grade (n=9) B-cell lymphomas tumors and low (n=4), 
intermediate (n=5), and high-grade (n=9) T-cell lymphomas tumors. Data are shown as means 
(columns) ± SEM (error bars). No significant statistical difference between groups was 
detected: P>0.05.  C) Representative western blot images from the analyses shown in A and B. 
The first two lanes represent the levels of K-48 polyubiquitinated in normal lymph nodes, 
followed by the expression levels of the protein in B-cell and T-cell lymphomas. β-Actin 
(ACTB) was used as a loading control.  
 
Figure 5. Serum VCP expression in canine lymphomas. Western blot analysis of the levels 
of VCP expressed in the serum of healthy dogs (n=22) compared to dogs diagnosed with high 
grade B-cell (n=9) and T-cell (n=9) lymphomas, intermediated grade B-cell (n=6) and T-cell 
(n=5) lymphomas, and low grade B-cell (n=5) and T-cell (n=4) lymphomas. Data are shown 
as means (columns) ± SEM (error bars). No significant statistical difference was recorded: 
P>0.05.  
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General discussion  
 Lymphoma is one of the most common cancers in dogs and the most common 
hematopoietic malignancy. Annually, anywhere between 24 to 107 new cases per 100 000 
dogs will be reported (22, 23), however it is believed that the true incidence to be in the 
thousands (24). Besides its high occurrence within the population, the disease is also known as 
a particularly aggressive cancer with a range of development rates (30). Although the genetic 
changes that lead to the disease's initial development can take decades, the cancer grows 
quickly and spreads to other parts of the body within a matter of months (30). For the animals 
undergoing chemotherapy, a high rate of remission can be recorded (22), unfortunately the 
overall survival 2 years after the initial diagnosis, remains under 10% (122). The low success 
of our treatments is mainly due to inexistent screening tools, prognostic indicators, and 
presence of residual disease after treatment. Despite this, few studies have focused on the 
validation of cancer biomarkers in veterinary medicine, valuable tools that could be useful in 
the earlier recognition of disease and its relapse, better diagnosis, and even as future 
therapeutic targets.  
 Medical advancements in the treatment of canine lymphoma will not only improve the 
quality and length of life of our companions, but also may further characterize an appropriate 
model in comparative oncology. Canine lymphoma provides a logical tool for translational 
research for human oncology. For example, the lymphoid neoplasm incidence in humans is 
reported to be as high as in dogs, more specifically 386 000 new cases world wide in 2012 
(123, 124). Furthermore, high-grade NHL was deemed comparable clinically and 
histologically with its canine counterpart (125). The lymphoproliferative disorder is 
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advantageous for study in a canine model because of the short remission times and the 
standard surgical removal of tumors followed by the histopathological analysis as a routine 
part of therapy (126), facilitating rapid data accrual. Moreover, veterinary oncologists have at 
their disposal the same chemotherapeutical drugs used in human medicine (most commonly 
vincristine, cyclophosphamide, L-asparaginase, and doxorubicin) proving that the treatment 
protocols could be very similar. (125). Finally, recent sequencing of the dog genome revealed 
around 19 300 protein-coding genes almost all having a human homologue (127). These 
considerations, taken together with the limited level of heterogeneity within the canine breeds, 
make the dog a powerful spontaneous model to identify possible heritable risks and genetic 
factors that are of pathological and clinical significance in lymphoma.  
 An important advance in the study of potentially novel veterinary cancer biomarkers 
came from the expansion of the field of proteomics. The idea behind this large-scale study of 
proteins is that malignant cells can increase the production of substances that are present in 
very low or undetectable concentration in the tissue or sera of healthy animals, but can prove 
valuable markers in cancer patients. This was the case of VCP, which was identified in several 
studies as a highly sensitive indicator of malignancy, often increased in sera and tumor tissue 
of cancer patients who do not otherwise display increased levels of the conventional markers 
for their cancer type (17, 18, 112-120, 128). More specifically, these studies determined that 
higher VCP levels are an indicator of poor prognosis in pancreatic ductal adenocarcinoma 
(114), pancreatic endocrine neoplasms (118), colorectal carcinomas (115), non-small-cell lung 
carcinoma (113, 128), hepatocellular carcinoma (119), gastric carcinoma (116), esophageal 
carcinoma (112), follicular thyroid cancer (120), gingival squamous cell carcinoma (117) and 
prostate cancer (18).  
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 VCP, a type II member of the AAA+ ATPase family, is a highly conserved molecular 
chaperone that acts as a ubiquitin segregase that remodels multimeric protein complexes by 
extracting polyubiquitinated proteins for recycling or degradation by the proteasome (96). 
Recent descriptive studies have shown that the protein is associated with anti-apoptotic 
functions and metastasis, making it an important factor for the survival and division of 
cancerous cells (112-117, 119, 120). These observations, taken together with the elevated 
VCP’s levels in the aforementioned human carcinoma, seem to suggest that cancers cells rely 
on intact VCP functions, identifying it as a potential valuable tool for cancer detection and 
monitoring.  
 One of the major goals of this thesis was the examination of VCP as potential 
biomarker for canine lymphoma. Biomarkers can be used for purpose of screening, diagnosis, 
prognosis, predicting drug efficacy, as well as an indicator of cancer recurrence (129). Despite 
their extensive use in human oncology, there are currently no markers used in veterinary 
medicine. Aberrant expression of VCP in canine lymphomas may potentially be a useful 
biomarker capable of predictive prognosis and cancer recurrence. As such, in this study, we 
are the first to show that VCP expression positively correlates with malignancy in B-cell 
lymphomas. Our research provides a new focus on the potential this protein has as a diagnostic 
biomarker for canine lymphoma. However, this hypothesis requires further investigation and 
some critical experiments, such as comparing VCP expression across several canine 
carcinoma and normal tissue, are missing in this work that would otherwise strengthen this 
conclusion.  
 Having identified a significant increase of VCP in high-grade B-cell lymphoma and 
intrigued by the possibility that the protein could be a marker of malignancy in canine 
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lymphoproliferative disorders, we wished to establish the commonality of VCP 
overexpression in lymphoma cell lines. Thus, in second part of our research we performed 
immunoblotting analysis of three lymphomas cell line, CLBL1, 17-71, and CL1. Preliminary 
evidence from our laboratory indicates that lymphoma cell lines had increased VCP 
expression compared to PBMCs. In accordance with the observations of other studies (93, 
106), this work adds to the hypothesis that VCP may be required for tumorigenic 
transformation and metastatic growth, making the protein a promising novel cancer 
therapeutic target. 
 Our research has provided new evidence in establishing VCP as a malignancy and 
possible new diagnostic biomarker in veterinary medicine. However our data also conflicts 
with findings of other studies. One previous study identified elevated serum VCP levels in a 
clinically significant proportion of human patients with NHL (17). Here, we investigated VCP 
expression in sera of dogs with lymphoma and attempted to make a correlation between sera 
and tumor levels of the protein. Our analysis did not identify significantly higher levels of 
VCP in the sera of sick dogs despite a clear increase in VCP expression in high-grade B-cell 
lymphoma tumors relative to low-grade tumors.  Furthermore, the study of Laguë (2012) 
found increased VCP levels in sera of several different cancer patients, such as granulosa cell 
tumors, ovarian carcinoma, breast cancer, and colon cancer, indicating the potential use of 
VCP as highly sensitive serum marker for several human cancers (17). The reasons we were 
not able to find the same high VCP serum levels as in human patients remain unclear. It is 
possible that dogs with lymphoma that have a tumor burden sufficient enough to permit VCP 
to enter the circulatory system do not live very long, succumbing to the disease before the 
protein’s levels are detectable. Unfortunately, we did not have information on the complete 
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staging of each case; as such comparison of tumor burden between specimens could not be 
conducted. Another possible reason for this statistically undetectable serum VCP levels might 
be due to tumor viability. Necrosis, apoptosis, and cell fragility are hallmarks of large tumors, 
increasing the leakage of proteins into the blood. It is therefore tempting to speculate that our 
dogs where not as far advanced into their disease to allow statistically significant amounts of 
VCP to accumulate in their sera.  Once again, due to lack of histopathological data, the 
amount of necrosis and apoptosis among different tumor types were not compared in this 
study. Finally, there is a distinct possibility that there are genetic differences between humans 
and dogs, which somehow prevent VCP reaching the circulatory system, even if the protein is 
overexpressed in high-grade tumors. While our data suggests that serum VCP levels may not 
be useful as a screening method for canine lymphoma, further studies of circulating VCP in 
dogs with cancer, including a larger sample of dogs with complete medical files, longitudinal 
studies with before and after treatment analysis, and improved detection methods, such as 
ELISA, is warranted.    
 In another study analyzing the critical role of VCP in the pathogenesis and progression 
of human non-small cell lung carcinoma (NSCLC), the authors show that VCP is significantly 
overexpressed in cancerous cells (128). Moreover, they observed, an accumulation of 
ubiquitinated proteins in NSCLC cell lines and tissues as compared to the normal controls 
(128). These results seem in contradictions with ours since, surprisingly, we were not able to 
detect any significant increase of polyubiquitinated proteins in lymphoma tissue. Although, 
this difference might be simply explained by the clinical and pathological distinction between 
the two cancers and the genetic differences between the two species, further analyses are 
required to elucidate the mechanisms behind the accumulation of ubiquitinated proteins or the 
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lack of thereof. Boyault et al. have demonstrated such a mechanism in which a balance 
between histone deacetylase 6 (HDAC6) and VCP might determine the degradation or 
accumulation of ubiquitinated proteins within the cell (130). As such, an increase in VCP, as 
the one observed in high-grade B-cell lymphomas, would lower the levels of polyubiquitinated 
proteins (130). On the other hand, an increase of HDAC6 and a subsequent decrease of VCP 
in the cells seem to favor the accumulation of polyubiquitinated proteins (130).  
 Differences between our results and those presented in the aforementioned studies 
might also reflect the limitations of the present research. Among them we can mention: the 
small N, the unknown normal expression of VCP in dog sera and tissue, the use of western 
blot as means of quantification, and the lack of a pure B-cell population as normal control. All 
these reasons combine to make immunoblotting quantification and immunohistochemistry 
staining difficult to interpret and in some situations, such as data analysis, impossible to run 
statistical tests that require normal distribution and variance. Some of these problems can be 
addressed in future studies by screening of a much larger cohort in order to gain statistical 
power and determine the spectrum of VCP expression in healthy animals and those with 
cancer. Large scale measurement will require the development of a high-throughput ELISA 
assay design for VCP, as western blots present certain pitfalls in terms of densitometry 
quantification and technical practicality that could have a major influence on the reported 
results (131). Finally, although normal lymph nodes might represent a good control for 
tumoral tissue, they do not contain a true population of normal lymphocytes. The existence of 
different other types of cells might influence the measured intensity of western blot’s protein 
bands, thus justifying the use of a pure population of B-cell lymphocytes as control in future 
studies.  
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 The fact that this study included for analysis only normal dogs and dogs with 
lymphomas is both a strength and limitation. The strength of analyzing VCP only in 
lymphoma is that the resulting protein overexpression can be considered to be sensitive to this 
type of tumor. However, it is also a limitation in that VCP might not be specific only to 
lymphoma, but present increased levels in other canine cancers, as determined for human 
malignancies by Laguë et al (17). Furthermore, we are mindful that certain inflammatory 
chronic diseases (CID) may cause VCP levels to increase, as it occurs with essentially all 
serum markers described to date (132). An ideal study design should also include samples 
from dogs with chronic inflammatory diseases such as, chronic arthritis, renal disease, mild 
liver disease, and/or inflammatory bowel disease. These conditions are frequently encountered 
as concomitant illnesses in cancer patients and the question of whether or not VCP is elevated 
in the CID population has not been fully answered. Incidence of CID is at its highest in dogs 
over 10 years of age, the same population that is likely to be often diagnosed with cancer (32). 
Therefore, it would be wise to clarify if there is a relationship between CID and VCP before 
using this marker to diagnose or make prognosis in canine lymphoma. 
 The authors also consider that it would have been best if the study had age and 
treatment-matched dogs. Since old age is significantly related to chronic diseases and previous 
medical conditions that required treatment, this study would have been better served if age and 
treatment-specific VCP values/cut-offs could have been reported. Understanding if VCP levels 
are altered by advanced age or treatment protocols could be an important objective for a 
further study. Furthermore, a better study design would also include a pre and post-treatment 
analysis of the protein levels. This would serve to establish VCP as a future recurrence and 
treatment follow-up marker.    
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  Another limitation of this study is the absence of sufficient clinical data from CCOGC 
to establish any potential correlation between VCP levels and clinical features of dogs with 
lymphoma. An interesting correlation that could have brought more insight to the recorded 
VCP levels is the association between the protein’s expression and the tumor size at the time 
of the excision. Moreover, additional information on recurrence would have allowed us to 
determine if higher VCP levels correspond with the end of the remission. Although we did 
received the survival time of each dog from the moment of diagnosis, no survival related 
correlation was performed since the files did not mentioned if the dog succumbed to its 
disease or was euthanized at the request of the owner. This problem can be addressed in future 
studies by asking the exact reason of death and eliminating the euthanasia cases. 
 Only a very limited number of anti-canine antibodies are commercially available as the 
dog model system is only recently gaining acceptance. Thus, short of generating new 
antibodies, the only way to study protein expression in canine samples is to validate currently 
available antibodies. Many of these are anti-mouse, anti-rat, anti-rabbit, and anti-human 
antibodies and, considering that VCP is a highly conserved essential AAA+ ATPase protein 
(93), they had a good chance of working in the canine model. We approached antibody 
validation by making sure a single band of the expected size, 97 kDa, was obtained in 
preliminary western blotting. This, undoubtedly, contributed to the reliability of VCP 
measurement in canine malignancies by western blot and immunohistochemistry.  
 Finally, another slight limitation to this study is that the control dogs (normal dogs) 
came form a university-wide announcement. An ideal control population would have been 
recruited from the same population as its cases. Therefore, ideally all subjects would have 
 95 
been recruited from CCOGC. However, it is not unusual for preliminary studies to have 
control samples that are not collected through the exact avenues as the cases.   
 Further studies should focus on the sensitivity of this marker in a broader canine 
population. A larger case-control study in populations affected by canine lymphoma needs to 
be conducted. Pre-treatment blood draws should be collected when a cancer case is first 
suspected. Cases also should be followed-up long-term and serial VCP measurements should 
be taken (at regularly scheduled follow-up visits) after chemotherapy treatments are 
completed, to determine if their values decrease in the period after treatment. The same 
procedure should be followed during remission in order to detect any association between 
VCP levels and the return of the disease. By conducting the study in this manner, further 
correlations that could establish VCP as a promising prognosis biomarker could be made. 
Furthermore, important confounding factors such as, the affect of chemotherapeutic drugs on 
VCP’s levels, could be eliminated. 
 If a larger case-control study were to verify VCP as a biomarker for canine lymphoma, 
then studies could also be conducted in other types of cancers. For example, a study could be 
conducted in dogs that have mammary cancer, another type of malignancy very often 
encountered in veterinary medicine (21). One study has already shown that women with breast 
cancer express higher VCP levels, without displaying increased levels of specific serum tumor 
markers for their cancer type (17). Since the cancer cells seem to be dependent on intact VCP 
functions for tumor growth and metastasis (128), it is not unlikely that the protein could be 
elevated in more than one type of canine cancer.  
 Determination of the efficacy of this marker in a separate large group, using healthy 
controls could represent the main goal of a future study. If the marker is again decided to be 
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sensitive and specific enough to warrant further study, a separate group of dogs with benign 
tumors such as, infiltrative lipoma, histiocytoma, basal cell tumor, cysts, fibroma, etc., should 
be studied in order to determine the usefulness of VCP in discriminating between dogs with 
cancerous and non-cancerous lumps. 
 Finally, this study was designed to determine the potential use of VCP as sensitive 
cancer biomarker for canine lymphoma, not to elucidate causes or pathways. There are a 
number of additional studies that could be performed to further investigate the roles of VCP in 
canine lymphoma. For instance, inhibition of VCP expression in tumor cell lines with the VCP 
inhibitor Eeyarestatin 1 (Eey1) (133) could allow long-term chemosensitivity and proliferation 
assays as well as other studies of tumor aggressiveness (e.g. colony formation) to be 
performed. As the protein seem to have a low expression in normal tissues, one could 
hypothesize that systemic blocking of VCP in cancer patients would have only limited side 
effects and may prove an effective method of limiting tumor cell invasion and metastasis. 
Similarly, stable blocking of VCP in PBMCs may provide further insight into its cellular role 
and the side effects if used as a future therapeutic target. Assessment of this methodology in 
canine models may provide an excellent platform for the development of a new anti-
lymphoma treatment and to obtain a better understanding of the functions VCP has within the 
cell.  
  The extent to which VCP will be a clinically useful cancer biomarker, beneficial in the 
prognosis and monitoring of high-grade canine lymphomas, will be fascinating to learn as the 
field moves forward. The contribution made by this thesis defines the base of a pyramid of 
investigations into the area of cancer biomarkers in veterinary medicine. Many questions 
remain about the specific nature and potential functional role of VCP in tumorigenesis. 
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Therefore, more work remains to be done for a more complete characterization of VCP and 
establishing a direct causal link between its overexpression and canine lymphoma. 
  
 
Conclusion 
 The present study has examined, for the first time, VCP expression in sera and tumor 
tissues of dogs with lymphomas via both immunohistochemistry and western blotting. 
Statistically significant differences were detected in VCP expression between high-grade and 
low-grade B-cell lymphomas, but not in T-cell lymphomas or serum samples relative to 
controls. In conclusion, we report that VCP levels correlate with malignancy in canine B-cell 
lymphoma. Although further studies will be necessary to substantiate the role of VCP as a 
potential new prognostic biomarker, these findings represent the first step towards an 
important advancement in the field of veterinary tumor biomarkers.  
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